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The UK Anthrax vaccine (AVP) is an alum precipitate of a sterile culture filtrate of the Bacillus 
anthracis Sterne strain designed to maximise the production of protective antigen (PA). 
Although AVP has been in use for decades, several of its fundamental properties are poorly 
understood, including its exact composition, the extent to which proteins other than PA may 
contribute to protection, and how the degree of protection may differ between individuals. 
 
This study involved three innovative investigations. Firstly, the composition of AVP was 
analysed using liquid chromatography tandem mass-spectrometry (LC-MS/MS). This required 
the development of a novel desorption method for releasing B. anthracis proteins from the 
vaccine’s aluminium-containing adjuvant. Secondly, computational MHC-binding predictions 
were made for the eight most abundant proteins of AVP using the NetMHCIIpan tool, focusing 
on the most common HLA alleles in several ethnic groups and multiple B. anthracis 
strains. Thirdly, antibody levels and toxin neutralising antibody (TNA) levels were measured 
for both PA and lethal factor (LF) in sera from AVP human vaccinees. 
 
Using LC-MS/MS it was demonstrated that AVP is composed of at least 138 B. anthracis 
proteins, including PA (65%), LF (8%) and edema factor (EF) (3%). NetMHCIIpan predicted 
that peptides from all eight abundant proteins are likely to be presented to T cells, a pre-
requisite for protection; however, the number of such peptides varied considerably for different 
HLA alleles.  
 
These analyses highlighted two important properties of the AVP vaccine that have not been 
previously established. Firstly, the effectiveness of AVP within humans does not depend on 
PA alone; there is compelling evidence to suggest that LF has a protective role, with 
computational predictions suggesting that additional proteins may be important for individuals 




with specific HLA allele combinations. Secondly, in spite of differences in the sequences of 
key antigenic proteins from different B. anthracis strains, computational analysis suggested 
that these do not affect the protection that AVP affords to strains other than the vaccine’s 
source strain.  
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1.1 Project Aims and Objectives 
 
Bacillus anthracis is a highly virulent bacterium that is responsible for causing Anthrax. Anthrax 
spores survive in the environment for a long time, are easily transmitted, and are associated 
with high rates of morbidity and mortality. For these reasons, Anthrax has gained increasing 
attention as a potential bioterrorism agent. As a consequence, government agencies are 
interested in stockpiling Anthrax vaccines that exhibit long-term stability and efficacy as a 
means to safeguard public health through mass immunisation, should the need arise.  
 
There are two widely-used vaccines against Anthrax: the US Anthrax Vaccine Adsorbed (AVA) 
vaccine, and the UK Anthrax Vaccine Precipitate (AVP) vaccine. AVP, which has been in 
production since the 1950s and is now manufactured by Porton Biopharma Ltd (PBL), is the 
focus of this research. AVP is, in essence, an alum precipitate of a sterile culture filtrate of the 
B. anthracis Sterne (34F2) strain. Previous proteomic studies [1, 2] have shown that AVP 
contains at least 21 proteins including protective antigen (PA), lethal factor (LF) and edema 
factor (EF). However, the exact composition of AVP remains unknown, although – perhaps 
significantly – it is thought to contain more LF than AVA, based on antibody titres measured 
in sera from animal or human studies [3-5].  
 
One of the main objectives of this project was to identify and quantify proteins in AVP. This 
was done using highly sensitive tandem mass spectrometry (LC-MS/MS) methods. An 
introduction to the technique is detailed in Section 1.5. The MS work carried out on AVP is 
described in Chapter 3. Potassium aluminium sulphate (alum) is used as an adjuvant in AVP. 
In order to characterise the proteins in AVP using LC-MS/MS methods, the proteins in AVP 
needed to be desorbed from alum. The development of a novel desorption method is 
described in Chapter 2. 




Numerous studies have confirmed that PA is the principle immunogen of both AVP and AVA, 
with anti-PA antibody and TNA (toxin neutralising antibody) levels generally accepted as 
correlates of protection when measuring vaccine efficacy [3, 6, 7]. These terms are explained 
in more detail in Section 1.3.3. However, it is currently unknown whether AVP proteins other 
than PA have a significant protective role. Several studies have highlighted the additional 
protective role of LF, either because it enhances the PA-specific antibody response [6, 8, 9], 
or via the independent protective role of anti-LF antibodies [3, 10, 11]. Additionally, EF is 
shown to protect from B. anthracis spore challenge in animal studies [12, 13], and that anti-
EF antibodies can neutralise Edema Toxin (ET) [14]. Other B. anthracis proteins such as cell 
wall proteins are also shown to trigger a protective immune response against Anthrax in mice 
[15].  
 
In Anthrax research, there has been a heavy reliance on animal studies, owing to the life-
threatening nature of B. anthracis and the low rates of human infection. Large-scale studies 
of human AVA vaccinees are possible because of mandatory US military vaccination 
programmes, whereas comparable studies for AVP are infeasible, given the comparatively 
smaller number of AVP vaccinees. One AVA study involving 1000 vaccinated individuals 
concluded that African Americans have lower toxin neutralising antibodies than European 
Americans [16], raising the possibility that genetic differences play a role in the immune 
response to AVA and calling into question the relevance of non-human studies.  
 
Given their known associations with ethnicity and with differential responses to vaccination, 
HLA haplotypes are prime candidates as potential genetic factors underpinning the 
stratification of human responses to Anthrax vaccines. Computational studies were carried out 
to predict MHC-binding (a pre-requisite for T cell response) for the most abundant proteins of 
AVP (these were identified by LC-MS/MS studies – Chapter 3). The differences in peptide-
MHC binding were investigated across common HLA alleles in several ethnic groups and 
multiple B. anthracis strains. Section 1.6 gives a brief introduction to the underlying 




computational methods. Computational work carried out in this project is detailed in Chapter 
4. 
 
Finally, a small proof of concept study was designed to characterise the immune response 
from PA and LF in human AVP vaccinees (Chapter 5). This study evaluated T cell response 
by measuring IFNy and IL10 cytokine response, anti-PA IgG, anti-LF IgG and TNA levels in 




1.2.1 Bacillus anthracis 
 
B. anthracis is a highly virulent, non-motile, encapsulated, gram-positive, rod shaped, spore 
forming, aerobic, facultative unaerobic bacterium (Figure 1) [17, 18]. Exposure to B. anthracis 




Figure 1 - Gram stained B. anthracis (1500x). Typically, the cells are 1-1.2µm in width x 3-
5µm in length with distinctive square ends. The endospore is ellipsoidal in shape and is located 
in the middle of the cell [19]. 
 




1.2.2 Anthrax Spore 
 
Robert Koch first observed that the bacterium associated with Anthrax formed endospores in 
1877 and demonstrated the disease by injecting into animals [20]. His work on Bacillus 
anthracis lead to the development of Koch’s four postulates, which became widely accepted 
principles in microbiology: first - the microbe is present in each case of the disease, second - 
the microbe can be taken from infected host and grown independently, third - when the 
microbe is introduced into healthy host, it causes disease, fourth - the microbe can then be 
isolated from the new infected host and identified to the source microbe [21]. 
 
An Anthrax spore is a special cell type produced by the bacteria in response to starvation. It 
lacks metabolic activity and is resistant to various environmental stresses such as heat, 
chemicals, desiccation, starvation and other stresses [22-24]. Hence, the spore can survive in 
the environment for decades in its dormant state; however, when the spore senses the 
presence of nutrients in a suitable host, it can rapidly return to a vegetative state. This also 
helps it survive the host defence systems after entering the host and before secreting toxins 
that cause disease when it has reached suitable location in the host after germination [25].    
 
The spore is formed of a series of concentric shells, and with each shell performing a specific 
function. First on the inside, there is a peptidoglycan layer which surrounds the spore core 
(containing the chromosome). Then there is a protein shell that can resist a variety of stresses, 
and on the outside, there is another protein and glycoprotein layer that is important for surface 
interactions with the environment and with the host [25].  
 
1.2.3 B. anthracis Virulence Factors 
 
B. anthracis has two virulence factors, namely the poly-D-glutamic acid capsule and the 
Anthrax toxins. It contains a single chromosome and two extrachromosomal plasmids. The 




poly-D-glutamic acid capsule is encoded by the pXO2 plasmid (182 kb) and suppresses 
phagocytosis by immune effectors. Anthrax toxins is an A/B type tripartite toxin, encoded by 
the pX01 plasmid (96 kb) [26-28]. These toxins are the main virulence factors of B. anthracis 
[18, 26-29]. The toxins are formed from the synergistic effects of three proteins – protective 
antigen (PA), lethal factor (LF) and edema factor (EF). These proteins are not toxic 
individually, but PA binds with LF to form lethal toxin (LT) and with EF to form edema toxin 
(ET). Typically, bacteria release toxins into the host as a survival strategy, to promote bacterial 
spread and growth and suppress host immune response. The function of PA, LF and EF, and 
their effects on the host immune system are detailed later in Section 1.3. 
 
1.2.4 Exposure to Anthrax and Mortality 
 
Exposure to Anthrax spores can result in high levels of morbidity and mortality. Anthrax 
typically affects wild or domestic herbivorous animals in its natural state. Human exposure to 
Anthrax is usually due to contact with infected animals or their products. There are three 
possible routes of exposure to Anthrax spores - cutaneous, gastrointestinal and pulmonary. 
People working in the tanning industry, woollen mills and veterinarians are at a high risk of an 
Anthrax infection. Recently, Anthrax infection was reported in class IV drug users due to 
contaminated heroin in Scotland [30].  
 
Cutaneous Anthrax infection is the most common type of Anthrax and accounts for more than 
95% of total cases. It is caused by the vegetative bacteria or its spore coming into contact with 
cuts or abrasions on the skin. The mortality rate for cutaneous Anthrax is approximately 20% 
without antibiotics. Clinical symptoms of cutaneous Anthrax develop within 1-2 days of 
exposure with the formation of a pruritic papule or vesicle that enlarges and erodes into a 
necrotic ulcer and subsequently into a black eschar. Other related symptoms such as fever, 
myalgia, swollen glands, headache and vomiting also persist. If the infection is not treated, it 
can progress into compartment syndrome in the affected area [17, 18]. 




Gastrointestinal Anthrax is caused by the ingestion of contaminated meat. The mortality rate 
for gastrointestinal Anthrax is approximately 25-75% with antibiotics, depending on the stage 
of infection and the start of treatment. The incubation period can range between 1-7 days. 
Clinical symptoms of gastrointestinal Anthrax include pharyngeal lesions with sore throat, 
difficulty in swallowing, marked neck swelling and regional lymphadenopathy, or intestinal 
infection showing symptoms of fever, severe abdominal pain, massive ascites, hematemesis, 
and bloody diarrhoea [17, 18].  
 
Inhalation Anthrax is the most severe and rare form of Anthrax, caused by breathing in Anthrax 
spores. The mortality rate for inhalation Anthrax is 45-90% with antibiotics, depending on the 
stage of infection and the start of treatment. The incubation period ranges between 1-43 days 
post exposure. Clinical symptoms of inhalation Anthrax start with fever, chills, cough, chest 
pain, headache, myalgia and malaise for the first few days. When the lymph nodes are 
overwhelmed with Anthrax toxin, the toxin ends up entering systemic circulation, resulting into 
acute respiratory distress with pulmonary edema and pleural effusion, and eventually severe 
breathlessness, hypoxia and septic shock [17, 18].  
 
1.2.5 Anthrax Incidences 
 
Anthrax incidences are rare and it is estimated that there are approximately 1000-2000 deaths 
per year worldwide [31]. However, Anthrax has gained significant attention as a bioterrorism 
agent. The first reported use of Anthrax as a biological agent was during World War I, when 
Germany wanted to spread it to the Allied Forces by contaminating livestock feed [32]. Post-
World War I and II, many countries instigated research into Anthrax vaccines [33]. Eventually 
in 1972, a treaty was signed between 103 countries to never use such biological warfare 
agents. Despite that, the bioterrorism threat of Anthrax continued during the Cold War and the 
Gulf War in 1991. In recent times, there is a threat from individuals and terrorist groups to use 
Anthrax as a bioterrorism agent. There have been two reported incidents of such attacks 




namely the 1995 attack by the Aum Shinrikyo cult in Japan [34] and the 2001 Anthrax mail 
event in the USA [18, 35]. Hence, for the purpose of public health preparedness, government 
agencies are interested in Anthrax vaccines that can be used for mass immunisation. It is 
important that the vaccine has long term safety and efficacy so that it can be stockpiled. 
 
1.2.6 Treatment for Anthrax post exposure 
 
The success of antibiotic treatment for Anthrax can be variable depending on the type of 
Anthrax infection. Nevertheless, the treatment is only effective if started early in the infection. 
Antibiotic treatment can kill the bacteria, but if Anthrax toxins have been released in the host, 
the treatment would be unsuccessful. Most cases of cutaneous Anthrax can be successfully 
treated with antibiotics involving a 60-day course of ciprofloxacin or doxycycline, with 
ciprofloxacin being the first line of treatment (EMA 2002). Other alternative antibiotic 
treatments include ofloxacin, levofloxacin and penicillin. Two or more types of antibiotics are 
necessary for the treatment of inhalation Anthrax [18].   
 
The antibiotic treatment regimen for Anthrax is lengthy and it can result in irregular medication, 
often resulting into antibiotic resistance. Although, antibiotic resistance to B. anthracis 
occurring naturally has been reported rarely, in vitro studies have shown that B. anthracis can 
develop resistance to ciprofloxacin, doxycycline and β-lactam antibiotics [36-39]. Cavallo et 
al., [40] studied antibiotic susceptibility in 96 B. anthracis isolates from France in vitro and 
reported that B. anthracis is susceptible to 25 different antibiotics. However, all of the isolates 
studied were resistant to cotrimoxazole, whilst 11 isolates were resistant to penicillin G and 
amoxicillin. Doxycycline and fluoroquinolones showed good activity; ofloxacin, pefloxacin, 
gatifloxacin, and levofloxacin are potentially suitable for the treatment of ciprofloxacin 
resistant strains. 
  




1.2.7 Current Anthrax Vaccines 
 
There are two types of Anthrax vaccines currently available for human use: 
1. Live attenuated vaccine – The vaccine contains spores from attenuated strains of B. 
anthracis. It was first licenced in Russia in 1953 for administration by scarification, and by 
subcutaneous injection in 1959. Booster injections are given on an annual basis [4, 18, 
35]. 
2. Cell-free vaccines 
a. AVP - The UK Anthrax vaccine Anthrax Vaccine Precipitate (AVP) is a sterile CF of 
avirulent B. anthracis Sterne strain precipitated adsorbed to alum. The vaccine was 
first licenced in the UK in 1978. The AVP immunisation schedule includes four 0.5mL 
intramuscular injections at 0, 3, 6 and 32 weeks. Booster injections were previously 
given on an annual basis [18], but since 2018 the booster frequency has been 
changed to 10 years. 
b. AVA - Anthrax Vaccine Adsorbed (AVA) is a culture supernatant of non-virulent B. 
anthracis V770-NP1-R adsorbed to aluminium hydroxide. The vaccine was first 
licenced in the USA in 1972. The AVA immunisation schedule includes five 0.5mL 
intramuscular injections at 0 and 4 weeks, and 6, 12 and 18 months. Booster 
injections are given on an annual basis, after the initial 18-month period [41]. 
 
1.3 Anthrax toxin 
 
As described earlier in Section 1.2.3, Anthrax toxins are formed from synergistic effects of 
three proteins namely PA, LF and EF. PA binds with LF to lethal toxin (LT) and with EF to form 
edema toxin (ET). PA is the 83 kDa receptor binding subunit, which facilitates the entry of LF 
(90 kDa) and EF (89 kDa) into the host cell.  
 
  




1.3.1 Receptor binding, Entry and Cellular Trafficking 
 
PA (83 kDa) is proteolytically activated by cleaving a 20 kDa fragment of PA at the N-terminus 
by furin-type proteases [28, 42-44]. The activated PA (63 kDa) monomer (PA63) is thus 
enabled to form a heptamer or an octamer, which can bind to LF or EF. Each PA63 oligomer 
can bind to three or four EF and/or LF molecules due to steric limitations [28, 44]. Mammalian 
endosomal lumen has low pH, which induces a conformational change in the PA oligomer. As 
a result, PA inserts into the lipid bilayer via cell surface receptors forming a prepore [42, 45-
47]. PA targets two cell surface receptors in mammalian cells namely, tumour endothelium 
marker 8 (TEM8) and capillary morphogenesis gene-2 (CMG2). TEM8 is also commonly 
known as Anthrax toxin receptor 1 and CMG2 is known as Anthrax toxin receptor 2. These 
proteins are homologous and contain an extracellular von Willebrand factor A (vWA) domain 
which binds to PA and its associated ligands [28, 46, 48]. LF and EF molecules are thus 
translocated into the cytosol by endocytosis [28, 42, 49-52].  
 
1.3.2 Mechanism of Action 
 
LF is the catalytic component of LT, which contains a thermolysin-like active site and a zinc 
binding consensus motif HExxH [53]. It acts as a zinc-dependent metalloproteinase [54], which 
cleaves mitogen-activated protein kinase kinases (MEKs) 1-4, 6 and 7 at the N-terminus. This 
results in the inactivation of three important mitogen-activated protein kinase (MAPK) cellular 
signalling pathways namely extracellular-signal regulated kinase (ERK) via MEK 1/2 [55], Jun 
N terminus kinase (JNK) via MEK 4/7 and p38 via MEK 3-6 [28, 56-61]. 
 
EF is the catalytic component of ET and acts as a calcium/calmodulin-dependent adenylate 
cyclase [62]. It converts intracellular ATP to cAMP 1000-fold faster compared to host adenylyl 
cyclases. Increased levels of cAMP disrupt many cell signalling pathways [63]. 
 




1.3.3 Immune Response to Anthrax toxins 
 
Since LT and ET are the major virulence factors responsible for causing Anthrax, this section 
summarises the effect of Anthrax toxins on the host innate and adaptive immune systems. 
These proteins suppress the host immune system by impairing the functions of several 
phagocytes including neutrophils, macrophages, monocytes and dendritic cells, T and B cells 
[28, 64].  
 
T follicular helper cells (TFH) are a type of CD4+ T cells that help the production of highly 
specific antibodies in germinal centres of secondary lymphoid tissue, that are associated with 
long-term humoral immunity [65, 66]. Secondary lymphoid tissues are those sites where 
lymphocytes and nonlymphoid cells facilitate the generation of immune responses to antigens; 
these include the spleen, lymph nodes, and mucosa-associated lymphoid tissues [67]. New 
evidence suggests that Anthrax spores germinate and release toxins at the site of infection, 
i.e. during inhalation infection in nasal-associated lymphoid tissues and during gastrointestinal 
infection in Peyer’s patches, before spreading to draining lymph nodes [68]. Given the 
importance of TFH cells for the generation of antigen-specific memory B cell antibody response 
and their relevance with respect to respiratory and gastro-intestinal lymphoid tissues, it is 
important to understand the factors underpinning the activation and induction of TFH cells 
during an anthrax infection or vaccination. 
 




Neutrophils (a type of white blood cell) are one of the first phagocytes recruited to fight 
infection. They migrate to the site of infection by chemotaxis, orchestrated by the expression 
of pro-inflammatory cytokines (e.g. IL-1β) and facilitated by actin filaments [69]. LT and ET 




suppress neutrophil function by suppressing their actin-based motility [70, 71]. Further, ET 
suppresses the expression of β2 integrin, which affects their surface adhesion ability [71]. LT 





Monocytes (a type of white blood cell) are recruited to phagocytose pathogens and  modulate 
cytokine-based inflammatory responses [73, 74]. Monocytes are derived from monoblasts in 
the bone marrow and differentiate into macrophages and dendritic cells [75-77]. LT is not 
thought to cause monocyte cell apoptosis directly but interferes with monocyte function. LT 
not only disrupts MAPK pathways, but also affects genes involving IL18, Toll-like receptor 
(TLR) [78], IFN alpha signalling and G protein family signalling pathway functions [74]. As a 
result, regulation of transcription processes, cytokine signalling pathways, actin regulation and 
signal transduction functions may be impaired [74]. The differentiation of monocytes into 
dendritic cells is also suppressed by inhibiting the production of chemokines [58, 74, 79-81]. 
ET has been shown to increase cAMP levels in human monocytes and adversely affecting 
cytokine expression (increased IL-1 and IL-6, decreased TNF-α) [82, 83]. Further, the 
production of heparanase may be suppressed, which plays a vital role in producing an 
inflammatory response [74].  
 
Research has shown that prior exposure to anthrax toxins modulate TEM8 receptor 
expression in monocytes [84]. TEM8 receptor expression in monocytes was shown to be low 
in naturally-infected individuals, whilst it was higher in AVP-vaccinated individuals and control 
individuals. This was also corroborated by the relative percentages of monocytes found to 
bind to PA within blood samples from these individuals. The hypothesis is that high expression 
of TEM8 receptors makes the individual more susceptible to anthrax infection. Despite the fact 
that AVP vaccinees would have been exposed to anthrax toxins, TEM8 receptor expression 




was high in monocytes from vaccinees. This could be attributable to differences in the 




Macrophages are critical components of the innate immune system that phagocytose 
pathogens. LT supresses macrophage activation and chemotaxis by disrupting MAPK 
pathways and inhibiting the expression of pro-inflammatory cytokines (e.g. TNF-α and IL-1β 
[85]) [81, 86]. LT also disrupts mitochondrial function, inhibits the expression of prosurvival or 
anti-apoptopic genes, and induces cell death by initiating proteasome and inflammasome 
dependent pathway [64, 87, 88]. 
 
ET supresses the phagocytic ability of human macrophages by increasing cAMP levels in the 
cells, which disrupts protein kinase A (PKA) dependent signalling pathways and actin 
remodelling processes [89, 90]. An in vitro study [91] suggested that ET also prevents 
phagocytosis by inhibiting the expression of TNF-α cytokine in murine macrophages. Although 
ET is thought to supress chemotaxis [86], evidence suggests that it may enhance the migration 
of infected macrophages (anti-inflammatory GPCR-activated macrophages) through lymph 




Dendritic cells (DCs) are part of both innate and adaptive immune systems. They are the 
antigen presenting cells responsible for delivering antigen-specific signals for mounting a T 
cell response. When a dendritic cell encounters a pathogen, it expresses inflammatory 
chemokines and recruits inflammatory effectors at the site of infection [93]. Typically, immature 
dendritic cells capture the bacterial antigens and accumulate them in the peripheral tissues. 
In lymph nodes, DCs become mature after going through terminal differentiation and present 




the bacterial antigens necessary for a helper T response (Th1 (interferon (IFN-γ) producing), 
Th2 (interleukin (IL)-4-, IL-5- and IL-13-producing) or Th17 (IL-17- and IL-22-producing)) [81, 
94, 95].  
 
Both LT and ET prevent the initiation of adaptive immunity by preventing DC activation and 
maturation. An in vivo study using a mouse model [96] demonstrated that LT prevents an 
antigen-specific T cell response by inhibiting the expression of pro-inflammatory cytokines and 
disrupting the MAPK pathways. Other studies [97, 98] have corroborated this finding in 
dendritic cells derived from mice bone marrow and lungs respectively and suggested that ET 
inhibits the production of IL-12p70, LT inhibits the production of IL-10, whilst both toxins 
collectively prevent the secretion of TNF-α. Further, it has been suggested that helper T cell 
differentiation in dendritic cells is suppressed by inhibiting the expression of TNF-α, IL-10 and 
IL-12 cytokines [99, 100]. LT also inhibits the production of chemokines from dendritic cells 
and epithelial cells in lungs [81, 99, 101], which prevents the recruitment of polymorphonuclear 
neutrophils at the site of infection [70]. LT is thought to kill immature dendritic cells and not 
mature dendritic cells [102]. On the other hand, ET promotes dendritic cell migration towards 
lymph nodes, thus allowing the spread of bacteria to other parts of the body [86, 103].  
 
1.3.3.2 Effect on T cells and B cells 
 
LT and ET are thought to disrupt the T cell and B cell functions [64]. PA in the toxins bind to 
the TEM8 (ANTXR1) and CMG2 (ANTXR2) receptors expressed by T cells [48, 104]. Both PA 
receptors have been found in mouse and human macrophages [105]. After the toxins have 
been transported into the cytosol, they disrupt MAPK and PKA signalling pathways, which 
control the expression of certain gene activation and proliferation of T cells [55, 106]. T cell 
activation is regulated by the proliferation of antigen-specific T cells [107]. 
 




In vitro studies [108, 109] have shown that LT inhibits T cell activation and proliferation by 
modulating the expression of certain cytokines (IL-2, TNF-α, IFN-γ, IL-5) and activation 
markers (CD69, CD25) in human T cells.  Comer et al., [91] demonstrated that LT and ET had 
inhibitory effects on T cell antigen receptor-mediated activation, secretion of cytokines (IL-3, 
IL-4, IL-5, IL-6, IL-10, IL-17, GM-CSF, TNF-α, IFN-γ) and proliferation of CD4+ T cells in a 
mouse model.  
 
Due to ET induced high cAMP levels, protein kinase A (PKA) pathway is activated, which 
inhibits Ras protein activation and disrupts the extracellular signal-regulated kinase (ERK) 
pathway via MEK1/2. Further, PKA induces inactivation of p38 and JNK mediated pathways 
[107, 110]. In addition, it is proposed that even after the toxins have been released into the 
cytosol, ET remains bound to the endosomes and continues to release high levels of cAMP. 
This results in high amounts of PKA locally, which indirectly affects T cell receptor (TCR) 
signalling [107, 111, 112]. Further, ET is thought to disrupt TCR signalling independently due 
to elevated cAMP levels [107]. Rossi Paccani et al., [113] demonstrated that ET disrupted 
TCR signalling in vitro using human T cells; it is thought to inhibit tyrosine kinase Lck activation, 
which adversely affects CD3ζ phosphorylation. Figure 2 shows the effects of Anthrax toxins 
on T cell activation and proliferation.  
 






Figure 2 - Effects of LT and ET on T cell activation and proliferation. LT disrupts MAPK 
signalling pathways and ET disrupts PKA-dependent pathways by elevating cAMP levels 
[107]. 
 
In addition, both LT and ET have been shown to restrict T cell chemotaxis [86]. This involves 
migration of naïve T cells to lymph nodes, preventing initiation of an adaptive immune 
response; and migration of T cell effectors from lymph nodes to peripheral tissues at the site 
of infection [86, 114]. Chemotaxis is regulated by chemokine receptors (seven spanning 
transmembrane receptors) which are coupled with Gi proteins. When there is an inflammatory 
chemokine response, chemokine receptors have an inhibitory effect on cAMP production. This 
instigates a tyrosine kinase-dependent pathway, which in turn activates MAPK signalling 
pathways. LT and ET suppress both APC and T cell chemotaxis by inhibiting the chemokine-
based activation of MAPK-dependent signalling pathway, thereby preventing the initiation of 
the adaptive immune response [86]. Figure 3 describes the effect of LT and ET on T cell 
chemotaxis. 






Figure 3 - Effect of Anthrax toxins on T cell chemotaxis. LT and ET inhibit the chemokine 
based activation of MAPK-dependent signalling pathways modulated by chemokine receptors 
[107].  
 
CD4+ T cells are very important in mediating the adaptive immune response. During TCR 
activation when the CD4+ T cells are presented with major histocompatibility complex (MHC) 
bound antigen by antigen presenting cells (APC), they differentiate into various types of helper 
T cells (e.g. Th1, Th2 and Th17). The differentiation of helper T cells depends on the antigen 
presented, the types of cytokine, or the lipid mediators produced [107, 115-117]. Th1 cells are 
usually responsible for cell-mediated immunity and aid macrophages by producing pro-
inflammatory cytokines. Th17 cells are also thought to help phagocytes with their functions by 
producing pro-inflammatory cytokines. Th2 cells have an important role in promoting the 
maturation of activated B cells into antibody producing plasma cells [107, 118-120]. ET has 
been shown to promote the differentiation of naïve CD4+ human T cells into Th2 and Th17 




cells by increasing cAMP levels and activating PKA-dependent pathways [107]. Figure 4 




Figure 4 - The effect of ET on helper T cell polarisation into Th2 and Th17 cell types. ET 
regulates TCR signalling and stimulates the expression of certain transcription factors, which 
in turn promote the expression of certain cytokines. The specific cytokines promote 
differentiation of naïve helper T cells into Th2 and Th17 cell types [107].  
 
LT is also thought to impact CD4+ T cell differentiation due to its interference with MAPK-
dependent signalling pathways, however the mechanism has not been studied yet [121]. 
 
LT and ET are believed to affect B cell activation, proliferation and antibody production [122]. 
Typically, helper T cells (specifically Th2) are required for the production of B cells, which 




produce antibodies specific to the required antigen (affinity maturation) and isotype switching 
(e.g. from isotype IgM to IgG) in maturing B cells [123, 124]. New evidence suggests that a 
subset of natural effector B cells can be generated independent of T cell help and are capable 
of isotype switching [125]. Th2 helper cells produce IL-4 transcription factor and CD40 ligand 
necessary for the terminal differentiation of B cells [126]. The differentiation of Th2 cells from 
its naïve precursor is dependent on the production of IL-4, IL-5, IL-10 and IL-13 cytokines 
[127]. Further, the production of IL-4 and IL-5 cytokines is dependent on PKA pathways. 
Although, increased cAMP levels (due to ET) promote Th2 cell differentiation, increased cAMP 
levels inhibit naïve Th cell development by regulating cytokine production. The IL-4 and IL-10 
cytokines are upregulated which promotes Th2 production, whilst inhibition of IL-12 cytokine 
inhibits Th1 production. Thus, ET disrupts Th1/Th2 balance by promoting differentiation of 
naïve CD4+ Th cells into Th2 cells [64, 128-131]. Further, ET has been described to inhibit B 
cell chemotaxis and modulates B cell cytokine production [63]. 
 
1.4 Immune Response to AVP/AVA Vaccination 
 
Both AVP and AVA were developed as prophylactic vaccines against Anthrax. Both vaccines 
are cell-free culture filtrate or supernatant of B. anthracis, grown in culture conditions designed 
to maximise the production of PA. The idea is that the generation of anti-PA antibodies post 
vaccination can protect the individual from subsequent Anthrax infection. Anti-PA antibodies 
are thought to prevent the toxin functions at many stages including binding of PA to its 
receptors, activation of PA, LT and ET formation, and translocation into the cell [132], thus 
neutralising the toxins from Anthrax infection. Hence, when measuring efficacy of AVA/AVP 
vaccination, anti-PA antibody titres and toxin neutralising activity (the capacity of the anti-PA 
antibodies to neutralise LT in vitro) are measured. These are generally accepted as correlates 
of protection [6, 133-138]. 
 




The production of anti-PA IgG antibodies post AVP vaccination describes a predominant T 
cell-dependent immune response; a robust CD4+ T cell response generates a mature antibody 
response (B cell) associated with T cell class switching (IgM to IgG) and the development of 
memory B cells of higher affinity and that are longer-lived. A T cell response is generated 
when foreign antigens are taken up by specific antigen-presenting cells (APC) and 
proteolytically digested into small peptides. Major Histocompatibility Complex (MHC) 
molecules bind to a number of these peptides and present them on the APC surface. In 
humans, MHC molecules are described as Human Leukocyte antigen (HLA). The formation 
of antigen-MHC complex enable the presentation of antigen-MHC complex on the APC cell 
surface [139]. CD4+ helper T cells or CD8+ cytotoxic T cells recognise the peptide-HLA II or 
peptide-HLA I interaction respectively and promote the expression of co-stimulatory effectors. 
Only a subset of peptide-HLA complexes are immunodominant.  
 
1.4.1 Characterisation of the Immune Response 
 
1.4.1.1 Antibody Subtypes 
 
There are five isotypes of immunoglobulin (antibody) molecules found in human blood sera: 
IgA, IgD, IgE, IgM and IgG. They are differentiated based on the type of heavy chain they 
contain [140]. 
 
The IgM isotype constitutes around 5% of all antibodies in blood sera. It is the first class of 
antibody produced on exposure to an antigen in the early stages of the primary antibody 
response. It is the largest in size, typically exists as pentavalent identical sub-units, attached 
by disulphide bonds. It has high binding strength and plays an important role in activating the 
complement system and agglutination [140]. Since this is the first major antibody class 
produced on exposure to an antigen, it might be important to measure IgM titres during the 
onset of anthrax infection or vaccination.  




IgD antibodies are secreted in small quantities on the surface of mature B cells, mainly 
functions as a B cell antigen receptor, and are co-expressed with IgM antibodies in naïve B 
cells.  
 
IgG is the most common isotype of antibodies (70-75%), and is produced in large quantities 
during the secondary immune response. It exists as a monomeric subunit, activates 
complement system, binds to Fc receptors on macrophages and neutrophils, and is 
responsible for initiating the antibody-dependent cell-mediated cytotoxicity (ADCC) response. 
Depending on the molecular weight of the antibody, the position of the disulphide bonds and 
the size of the hinge region, IgG can be further divided into four sub-classes - IgG1, IgG2, 
IgG3, and IgG4. Generally, IgG1 and IgG3 production is triggered by proteins, whereas IgG2 
and IgG4 is triggered by foreign polysaccharides [140, 141].  
 
IgA isotype constitutes around 10-15% of all antibodies in blood sera; it is also the most 
prevalent class of antibody in secretions (respiratory and intestinal secretions, saliva, tears, 
breast milk). IgA exists as a monomeric subunit in blood, whilst it is dimeric in secretions. It 
has two subtypes (IgA1 and IgA2), based on differences in the hinge region. IgA provides the 
primary antibody response against inhaled and ingested pathogens at mucosal surfaces [140]. 
Hence, this antibody class could be important in characterising anthrax infections, given that 
gastro-intestinal and inhalation anthrax act across mucosal membranes.  
 
IgE is the least prevalent antibody isotype in blood sera (typically a 10,000 times lower 
concentration that IgG). This isoform is increased significantly in allergic reactions. In response 
to pathogens, IgE binds to mast cells in tissues and blood via specific receptors in response 
to pathogens, acting as passively-acquired receptors for antigens. This results in recruitment 
of eosinophil at the site of infection and destruction of pathogens via ADCC-type mechanisms 
[140]. 
 




1.4.1.2 Characterisation of the Immune Response to AVA and AVP 
 
Baillie and co-workers [142, 143] characterised the types of anti-PA IgG detected in AVP 
vaccinees who had received the full AVP vaccination schedule. These studies confirmed that 
IgG1 was principally generated; however, IgG2, IgG3 and IgG4 were also detected in the serum 
samples from AVP vaccines. The presence of IgG2 and IgG3 indicates Th1-generated 
response, whilst IgG1 and IgG4 represent a Th2-generated response [144].  
 
Allen et al., [145] evaluated T cell response from AVP in Gulf war veterans who had been 
vaccinated 10-15 years prior to the study. Based on cytokine profiles, they reported that the 
vaccinees has long-lasting mixed Th1 (IFN-γ and IL-2) and Th2 (IL-13) response. Two other 
studies [6, 146] have corroborated this finding and reported mixed Th1 and Th2 cytokine 
response induced by AVA vaccination. Kwok et al., [147] evaluated CD4+ T cell immune 
response in 36 AVA vaccinees and reported bias towards PA-specific Th2 response (higher 
amounts of IL-5 and IL-13 in comparison to IFN-γ). Further, PA-specific pre-Th2 memory T 
cells were also detected in the vaccinees, meaning that the development of PA CD4+ T cells 
was skewed towards a Th2 response, due to the pre-exposure of PA in AVA vaccinees. 
 
1.4.2 Vaccine Efficacy 
 
AVP and AVA are known to be efficacious based on historical animal and human data [7, 18, 
148-151]; however, the immune response is not fully understood. The only efficacy data in 
humans is the observation that since AVP vaccination started in 1958, there was a decrease 
in the number of Anthrax infection cases in the employees at the Government Wool 
Disinfection Station in Liverpool [18, 149]. A field study in the US [7] found 92.5% AVA 
vaccination efficacy in workers exposed to inhalation Anthrax at four US mills. Protection had 
failed in workers who had either incomplete, placebo or no vaccine inoculation; except in one 
case where protection failed in a vaccine-inoculated individual.  




Several hurdles are encountered when assessing the data from various studies. Variables 
such as different animal models, different B. anthracis strains, route of infection, vaccine 
dosing schedules, etc. further complicate the issue and have prevented robust conclusions 
from being drawn. Further, the genetic diversity of the human host has also been reported to 
contribute to differences in immune response.  
 
1.4.2.1 Animal Models 
 
The pathophysiology of Anthrax infections varies in different animals. Vaccine efficacy in 
different animal models is also different [18, 33]. AVP is shown to be least efficacious in mice, 
rats and guinea pigs, whilst it provides good protection in rabbits and monkeys. The non-
human primate model e.g. Rhesus macaque (being the closest to human) is considered to be 
the most suitable model for bridging animal data to humans and measuring probability of 
survival for vaccine efficacy [152]. However, it is unclear the extent to which genetic 
differences between humans and animals, such as those associated with MHC molecules and 
the encoding of T cell receptors, undermine the ability of animal models to provide reliable 
insights into the efficacy of the vaccine.  
 
1.4.2.2 B. anthracis strains 
 
Several studies have been carried out to assess whether AVP/AVA would be protective 
against different B. anthracis strains. Inhalation Anthrax challenge studies in guinea pigs [153-
155] demonstrated that AVP and AVA provided different levels of protection to different strains. 
It conferred full protection against the Vollum strain, limited protection against the Ames strain 
and showed no protection against the New Hampshire and penicillin-resistant strain, despite 
having high anti-PA antibody titres. AVA vaccination was shown to be protective against 18 
out of 27 B. anthracis strains in guinea pigs [156]. Another study found that the level of 




protection by AVA from 33 different B. anthracis strains varied considerably (6-100%) in 
guinea pigs [157]. However, AVA was shown to be protective in macaques and rabbits against 
several virulent B. anthracis strains in the same study. As mentioned previously, AVP and 
AVA are manufactured from avirulent Sterne strain and non-virulent V770-NP1-R strain, 
respectively. It remains to be assessed whether there are differences in sequences of key 
antigenic proteins in AVP and, if so, does this impact the protection afforded against different 
B. anthracis strains in humans? 
 
1.4.2.3 Route of Anthrax infection 
 
The route of Anthrax infection can also result in a differential immune response. The following 
studies in survivors of Anthrax infection demonstrate that the immune response varies 
considerably in different human hosts, depending on the type of Anthrax infection. Quinn et 
al., [158], reported that anti-PA IgG titres, TNA and memory B cell response, time course for 
production, and maintenance of antibodies varied significantly depending on the type of 
infection (inhalation or cutaneous Anthrax) in 22 patients. Anti-PA IgG was detected in 
inhalation Anthrax patients after 11 days and after 21-34 days in cutaneous Anthrax patients 
from the start of symptoms. Anti-PA IgG was detectable for 8-16 months in 6 survivors of 
inhalation Anthrax and 7 of 11 survivors of cutaneous Anthrax. PA-specific IgG memory B 
cells could be detected in all 6 survivors of inhalation Anthrax and in only 2 out of 7 survivors 
of cutaneous Anthrax. This suggests that the degree of protection afforded by AVP/AVA 
vaccination would also differ depending on the type of Anthrax infection encountered.  
 
1.4.2.4 Human Genetic Diversity 
 
Genetic diversity in humans can cause significant differences in immune response from 
AVP/AVA vaccination and vaccine efficacy. Baillie and co-workers [143] reported that anti-PA 
antibody titres in human AVP vaccinees varied significantly and suggested that this may be 




due to the genetic diversity of the human host. Further, a study found that despite having high 
anti-PA antibody titres in 200 AVA vaccinees, 43% of the samples lacked toxin neutralisation 
activity in vitro [16]. PA may not induce protective antibody immunity in some people due to 
immunodominant responses to non-protective PA epitopes [159].  
 
Another study evaluated the immune response generated in 1000 AVA vaccinees and 
described that serum samples from African American individuals had lower toxin neutralising 
activity than European Americans samples [160]. Similarly, Marano et al. [161] also reported 
differences in immunogenicity in 1564 AVA vaccinees as a result of human racial diversity. 
There are a number of factors that could contribute to such variation, including different 
epitopes being presented by MHC molecules, differences in HLA haplotypes, cytokine or 
cytokine receptor gene polymorphisms or differences in cell surface molecules [160, 162, 163]. 
Given their known associations with ethnicity and with differential responses to vaccination, 
HLA haplotypes are prime candidates as potential genetic factors underpinning the 
stratification of human responses to Anthrax vaccines. Indeed, a significant association 
between HLA-DRB1-DQA1-DQB1 haplotypes and anti-PA Ab titres has already been 
demonstrated for European-Americans vaccinated with AVA in a GWAS study. Specifically, 
three distinct haplotypes were associated with lower titres, with the HLA-DRB1*15:01-
DQA1*01:02-DQB1*06:02 haplotype having the highest statistical significance, and with the 
affect accentuated for homozygous carriers compared to heterozygous carriers [164].  
 
1.4.3 Composition of AVA / AVP 
 
The composition of AVA has not been published yet. However, studies indicate that AVA 
contains similar levels of PA and lower levels of LF, EF and certain surface proteins compared 
to AVP [4, 153, 160, 165-168]. 
 




The exact composition of AVP is unknown. Studies carried out by a group at the National 
Institute of Biological Standards and Controls (NIBSC) [1, 2] determined that AVP contains a 
complex mixture of at least 21 proteins from the B. anthracis proteome, including PA, LF and 
EF. The average PA and LF content in AVP supernatant is reported to be 3.71 and 0.99 μg/ml 
respectively, as determined by ELISA [18]. One of the main objectives of this project is to 
determine the composition of AVP using tandem mass spectrometry (LC-MS/MS) studies. An 
introduction to the technique is detailed in Section 1.5, the MS work carried out on AVP is 
described in Chapter 3. Potassium aluminium sulphate (alum) is used as an adjuvant in AVP. 
In order to characterise the proteins in AVP using LC-MS/MS methods, the proteins in AVP 
needed to be desorbed from alum. The development of a novel desorption method for proteins 
in AVP is described in Chapter 2. 
 
1.4.4 Are other AVP proteins Immunogenic? 
 
Although, PA is the main immunogen in both AVA and AVP, it is possible that other B. 
anthracis proteins could also play an important protective role against Anthrax. For instance, 
AVP is thought to contain more LF than AVA, based on antibody titres measured in sera from 
animal or human studies [3-5]. Many studies have highlighted the additional protective role of 
LF, either because it enhances the PA-specific antibody response [6, 8, 9], or via the 
independent protective role of anti-LF antibodies [3, 10, 11]. Ingram et al. [169] had reported 
that a strong, long-lasting CD4+ T cell response to LF was measured in both AVP vaccinees 
and cutaneous Anthrax patients.  
 
Another study reported that higher anti-LF antibody titres than anti-PA antibody were 
measured in two out of 4 AVP vaccinees [123]. Further, based on humoral immune response 
data from cutaneous Anthrax patients, Brenneman and co-workers [170] suggest that the anti-
LF IgG antibody response is fast and lasts longer in comparison to the anti-PA IgG response. 




These studies suggest that AVP contains significant amount of LF that could be playing an 
important role in protecting vaccinees against Anthrax.  
 
Additionally, AVP is thought to contain minute amounts of EF, based on anti-EF antibody titres 
measured in AVP vaccinee sera [14, 153], whereas AVA does not contain any EF [154]. EF 
is also shown to protect from B. anthracis spore challenge in animal studies [12, 13], and that 
anti-EF antibodies can neutralise ET [14]. Other B. anthracis proteins such as cell wall proteins 
are also shown to trigger a protective immune response against Anthrax in mice [15]. Baillie 
and co-workers [142, 143] further suggested that other components of AVP such as bacterial 
cell wall proteins may also trigger an immune response. An in vivo study in mice [15] 
corroborated this and demonstrated that EA1 (S layer protein) in combination with PA might 
contribute to protection during the early stages of infection.  
 
In this research, computational studies were carried out to predict MHC-binding (given that 
presentation by MHC molecules is a pre-requisite for a T cell response) for the most abundant 
proteins of AVP (as identified by LC-MS/MS studies – Chapter 3). The differences in peptide-
MHC binding were investigated for common HLA alleles in several ethnic groups and multiple 
B. anthracis strains. Section 1.6 gives a brief introduction to computational methods. 
Computational work carried out in this project is detailed in Chapter 4. 
 
1.5 Mass Spectrometry-based Proteomic Studies 
 
This section describes the “Bottom-up” proteomics workflow that was used to characterise 
AVP in this project. See Figure 5 for a Shotgun Bottom-Up Proteomics workflow. Tandem 
Mass Spectrometry (LC-MS/MS) analysis performed on proteolytically-digested proteins for 
the characterisation of proteins is known as shotgun “Bottom-up” proteomics [171]. The 
available approaches for sample preparation, mass analysers and data acquisition methods 
and data processing are described here. In a typical shotgun bottom-up proteomics 




experiment, the proteins are solubilised and digested with an enzyme to generate peptides. 
The peptides are then separated and fractionated usually by reverse phase (RP) 















Figure 5 - Shotgun Bottom-Up Proteomics Workflow 
 
 Solubilisation and Proteolytic Digestion 
 
For optimum proteolytic digestion efficiency, it is important that the protein is solubilised and 
unfolded for access to protease cleavage sites. Commonly-used solubilisation agents include 
organic solvents, surfactants and salts (e.g. acetonitrile [171-174], urea and SDS [171], 
custom-made surfactants such as ProteaseMax, Invitrosol, Rapigest, PPS Silent surfactant 
[171, 174], volatile surfactants such as Perfluorooctanoic acid and 1-butyl-3-methyl 




e.g. Trypsin, Lys-N, Lys-C 
Peptide Separation and Fractionation 
Reverse Phase Chromatography 
Mass Spectrometry Analysis  
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Common proteases used in bottom-up proteomics are detailed in Table 1. Each of the 
proteolytic enzymes has different cleavage specificity for cleaving at the amide or carboxyl 
bonds of protein residues by hydrolysis. Trypsin is the most widely-used proteolytic enzyme, 
often described as a “gold standard” [171].  
 
Protease Cleavage Specificity 
Trypsin Carboxyl side of Arg and Lys 
Endoproteinase Lys-C Carboxyl side of Lys 
Chymotrypsin 
Carboxyl side of Trp, Tyr and Phe; 
less specificity for Leu, Met and His 
Elastase Carboxyl side of Val or Ala 
Endoproteinase Lys-N Amine side of Lys 
Endoproteinase Glu-C Carboxyl side of Glu and Asp 
Endoproteinase Arg-C Carboxyl side of Arg 
Endoproteinase Asp-N Amine side of Asp and Cys 
 
Table 1 - Common Proteases used for Bottom-Up Proteomics (Adapted from [171]) 
 
 Mass Spectrometry 
 
Mass spectrometry has now become a technique of choice for proteomic studies due to its 
high sensitivity, accuracy and throughput. In simple terms, a mass spectrometer is composed 
of an ion source, a mass analyser and a detector. The ion source ionises the sample, the 
mass analyser measures the mass-to-charge ratio (m/z) of ionised analytes in vacuum and 
the detector records the intensity of each m/z value ion. In this section, the components of the 
mass spectrometer that are relevant to this project are described. There are other ionisation 




techniques or mass analysers available, however discussing those is beyond the scope of this 
project.  
 
1.5.2.1 Electrospray Ionisation 
 
ESI is known as a soft ionisation technique, as it is suitable for polar, thermally- unstable and 
least volatile samples [176]. This method can ionise a liquid sample, hence it is typically 
combined with reversed phase-liquid chromatography (RPLC) [171, 177, 178]. The sample is 
drawn up into a glass capillary (maintained at a high voltage), which aerosolises the sample. 
ESI is a soft ionisation process and does not generate fragmented ions. Further, ESI 
generates multiply-charged ions, which means that during peptide or protein analysis, the 
mass range can be optimal for data acquisition by commercial mass analysers [176, 179]. 
NanoESI is analogous to ESI, albeit at a lower flow rate (20-50 nL/min) [180, 181]. This means 
that lower sample concentration (nmol/mL) and volume are required, resulting in less 
interference from salt contaminants [180-182]. The nanoESI generates tiny droplets, allowing 
aerosolisation of samples without applying high heat or sheath gas [181].  
 
1.5.2.2 Mass Analysers 
 
The mass analyser generates accurate ion mass spectra data by separating ions based on 
their mass-to-charge ratio (m/z). Commonly used Mass Analysers for Proteomics work include 
linear ion trap, orbitrap, fourier transform ion cyclotron resonance, quadrupole and time of 
flight [183] [171, 178]. These mass analysers derive and measure peptide masses using 
different mechanisms, hence selecting a mass analyser is a trade-off between sensitivity, 
accuracy and speed depending upon the application [171, 178]. This section focuses 
exclusively on quadrupole and time-of-flight mass analysers only, as these are used in this 
work. 
 






Quadrupole mass analysers are popular for proteomics work, as they are operationally simple, 
relatively inexpensive and can perform both quantitative and qualitative mass analysis. A 
quadrupole mass analyser comprises of four parallel electrodes (cylindrical metal rods with a 
hyperboloidal interior surface) positioned at the same distance from the central axis, inside a 
vacuum chamber [176, 179]. See Figure 6 for a diagram of quadrupole mass analyser. These 
operate at relatively low vacuum levels compared to other mass analysers, enabling easy 
interface with an LC system [176].  
 
A quadrupole mass analyser has a high scan speed (6000 amu/sec), which enables a mass 
measurement range of up to 2000 m/z. This allows mass measurement in a practical range 
generating qualitative data. Furthermore, it can switch between high-speed scans, generating 
high-sensitivity quantitative data on multiple ions, known as selected ion monitoring [176].    
  







Figure 6 - Diagram of a Quadrupole mass analyser (Adapted from [176]). Ions enter the 
quadrupole through a small orifice (in z direction) under low applied voltage. An alternating 
direct and high frequency current voltage is applied to each electrode, oscillating ions in the x 
and y direction. Certain ions of a specific m/z attain stable oscillation under specific voltage 
conditions, enabling them to exit the quadrupole and reach the detector. Oscillations of other 
ions become unstable and collide with the electrodes and not be detected [176].  
 
2. Time of Flight 
 
A ToF analyser consists of an accelerator contained within a strong vacuum (See Figure 7 for 
a diagram of ToF). ToF can measure ions of any mass range. However, as a result linear ToF 
suffers from low resolution, as ions with similar m/z can have similar flight times. Reflectrons 
are used to improve resolution, by correcting initial kinetic energy dispersion and ToF 
difference by increasing the ion path length of the ion.  Essentially, the higher velocity ions 
would travel into the reflectron more deeply and thus take longer to reverse under a decreasing 
electric field (See Figure 8).  
 
 





Figure 7 – Diagram of a ToF mass analyser (Adapted from [176]). It extracts ions from the 
ion source in pulses or intermittently, and measures the time required by the ions to travel 
from the ion source to the detector (m/z ratio). 
 
 
Figure 8 - Schematic of a Reflectron in a ToF (Adapted from [184]). Two ions of the same 
m/z ratio but different initial kinetic energies are depicted in red and green colour. 
Consequently, the green ion has a longer path length than the red ion. 




 Tandem Mass Spectrometry (MS/MS) 
 
Different mass analysers are combined to allow mass analysis of LC separated peptides 
(MS1) and their fragments (MS2) [185]. This is known as tandem mass spectrometry (MS/MS).   
 
 Peptide Fragmentation 
 
The two most popular peptide fragmentation methods are collision induced dissociation (CID) 
[82] [171] and electron capture dissociation (ECD) [186] or electron transfer dissociation (ETD) 
[187]. This section focuses on CID only, as this was the peptide fragmentation method used 
in this work. 
 
Collision Induced Dissociation 
 
CID involves the acceleration of molecular ions in gas phase to high kinetic energy in vacuum 
using electric potential to collide with neutral molecules (e.g. helium, nitrogen or argon). During 
the collision, some of the ion’s kinetic energy is internalised, resulting in peptide bond cleavage 
and fragmentation of molecular ions into fragments. The fragmentation pathways mostly rely 
on proton transfer [171]. Fragmentation pathways can now be predicted (Figure 9 details the 
fragmentation ion nomenclature). 
 
 
Figure 9 – Fragmentation Ion Nomenclature for Peptides [171] 




In a beam-type CID on a quadrupole mass analyser, both precursor ion and fragmented ions 
are activated and dissociated, resulting in further dissociation of relatively unstable b ions into 
y-type ion fragments [171]. 
 
 Data Acquisition  
 
1.5.5.1 Data-Dependent Acquisition (DDA) 
 
Data-dependent acquisition is the traditional method of data acquisition. It involves 
identification and fragmentation of the high-intensity precursor ions with specific m/z values. 
This process is repeated until all of the high-intensity ions have been sampled.  The frequency 
of ion scans and fragmentation can be adjusted, based on signal-to-noise threshold. Figure 
10 shows a schematic of DDA. 
 
 
Figure 10 – Schematic of Data Dependent Acquisition (Adapted from [188]) MS scan 
selects the 3 most abundant precursor ions (blue, green and red), subsequent fragmentation 
generates MS/MS scans of each ion. 
 




Obviously, DDA creates a bias, where only most abundant proteins in the sample are 
identified. Reproducibility of low-abundance peptide quantification is challenging with DDA 
[189]. Further, repeatability in peptide identification decreases due to variability of LC and MS 
time alignment between replicate runs, along with inherent variability from ionisation method 
(e.g. ESI) [190]. 
 
1.5.5.2 Data Independent Acquisition (DIA) 
 
In DIA analysis, all peptides within a certain m/z window and retention-time range are 
fragmented at the same time. This process is repeated until all of the m/z windows and 
retention-time ranges are covered. This allows unbiased peptide identification and accurate 
quantification of all abundances [191].  
 
Different DIA approaches with different instrument types, duty cycles and precursor selection 
ranges have been described in the literature previously. Silva et al., [192] have described the 
MSE approach, which involves the fragmentation of all precursor ions and simultaneous 
acquisition of MS and MS/MS data at high and low collision energy. The precursor ion and 
fragment ions are then matched up by either retention time and/or mass difference. Figure 11 
shows a schematic of the DIA-based MSE approach. The MSE approach was shown to be 
more reproducible than the traditional DDA acquisition on MS/MS [193]. 
 






Figure 11 – Schematic of Data Independent Acquisition based MSE approach (Adapted 
from [194, 195]). The peptides are separated on reversed phase column, then ionised before 
entering triple quadrupole mass analyser. Precursor ions are fragmented, and MS and MS/MS 
data is acquired at high and low collision energy, simultaneously. The precursor ion and 
fragment ions are then matched up by either retention time and/or mass defect. 
 
Similarly, Panchaud et al., [196] have described the PAcIFIC approach, which involves 
fragmentation of precursors within a small m/z window of 2.5 m/z, where precursor selection 
is independent of ion count. PAcIFIC was shown to perform more efficiently than traditional 
DDA acquisition and identified hundreds of proteins across 8 orders of magnitude. The main 
difficulty with DIA analysis is that the resulting MS/MS spectra can be very complex [189], 
which increases the time required for data analysis, or else the DIA comprises a larger 
precursor selection window [191].  Recently, Aebersold and co-workers have described a DIA-
based SWATH approach, which is a targeted data extraction method [197], combined with 
software that facilitates automation (OpenSWATH) [191]. The SWATH method involves the 
selection and fragmentation of sequential 25 m/z ion windows across a 400-1200 m/z range 
and the generation of high resolution and accurate mass data. Peptide identification is done 




by matching fragment ion data with a spectral library containing prior information based on 
representative sample analysis. Further, OpenSWATH facilitates automated retention time 
alignment, chromatogram extraction, peak group scoring and statistical estimation of false 
discovery rate [191].  
 
 Peptide Identification  
 
Peptide identification is performed by matching the measured mass of peptides from MS/MS 
data with a protein library [185]. A theoretical protein sequence library based on relevant 
genomic data is supplemented with enzyme cleavage sites and the prediction of fragmentation 
ions. Search engine tools have been developed to search and analyse mass spectrometry 
data. The most popular tools include Sequest [198], Mascot [199], Andromeda [200], 
ProteinLynx Global Server [201] [201], OMSSA [202], X!tandem [203] and CRUX [204]. 
Several statistical algorithms have been developed to determine the false discovery rate 
(FDR) for a particular dataset, and thus limit the number of false identifications [205-207]. The 
most popular approach for determining FDR is to create a target decoy database [185, 208, 
209], which combines both a target sequence database and a decoy database. A decoy 
database is created by either reversing or scrambling the protein sequences from the target 
database. It is assumed that the sequences in these databases will not overlap and if they do 
the FDR rate will be very high.  
 
 Label-Free Quantitation 
 
There are several approaches to label-free quantification of proteins by LC-MS/MS. One of 
the most popular methods for relative quantification of proteins is spectral counting, which 
involves counting the number of times a peptide mass spectrum is measured [185]. Several 
studies have described other approaches for the relative quantification of proteins [192, 210-
213].  




More recently, label-free absolute quantification methods have been described. One of the 
most popular approaches is the incorporation of a standard of known concentration, creating 
a calibration curve and extrapolating the protein concentration [193, 214, 215]. Additionally, 
peptide peak intensity predictions can be made and these can help deduce absolute protein 
concentration [216]. Schwanhausser et al., [217] have described “iBAQ” for absolute 
quantification of proteins, which is an extension of the spectral counting method. This method 
involves dividing the number of theoretically observable peptides from the sum of peak 
intensities of all peptides from a specific protein for inferring proxy absolute protein 
concentration.  
 
Silva et al., [193] describe a method for the absolute quantification of proteins by LCMSE, 
known as the Hi3 method. This method calculates the average MS signal for the three most 
intense peptides of each protein and the internal standard. A universal signal response factor 
is calculated from the average MS signal of the internal standard (counts/mol of protein). The 
absolute protein concentration is derived by dividing the universal signal response factor from 
the average MS signal for the three most intense peptides for that protein. 
 
1.6 Computational Studies 
 
As described previously in Section 1.4.2, the assessment of Anthrax vaccine efficacy is 
complex. Firstly, owing to the nature of the organism, studies in humans is not possible. Owing 
to genetic differences between humans and animals, animal models cannot give us reliable 
insights into the human immune response from vaccination and its efficacy. Secondly, the 
genetic diversity of humans has been reported to cause significant variation in immune 
response from AVP / AVA. Even though high anti-PA antibody titres are measured in AVA 
vaccinees, TNA levels are low in some individuals and this raises questions about the efficacy 
of the vaccine. Previously, studies have focused on certain alleles for experimental feasibility 
[146, 169, 218, 219]. It is important that many alleles that represent the diverse human 




population are studied so that the potential differences in human ethnicities/populations can 
be investigated. This would not be feasible experimentally.  
 
Thirdly, there has never been a systematic study to investigate the efficacy of AVP in humans 
against different B. anthracis strains. For these reasons, in this project we have taken a 
computational approach. Computational tools that have been developed using large sets of 
experimental binding data have afforded the opportunity to gain insights into AVP protein-
specific CD4+ and CD8+ T cell responses by human hosts. These tools enabled us to 
investigate peptide-MHC binding affinities (peptide-MHC binding is a pre-requisite for a T cell 
response to develop) for multiple antigens in AVP across common HLA alleles. Further, the 
immunogenicity of PA, LF and EF proteins from AVP in humans was also investigated across 
several B. anthracis strains.     
 
The likelihood that a given T cell epitope will emerge as an important contributor to the host 
immune response is partly dependent on the specificity and affinity of the complex between 
(on the one hand) the relevant peptide bound to an MHC molecule and (on the other hand) a 
T cell receptor (TCR) T cell [220]. T cells are known to be antigen specific, which allows them 
to distinguish between self and non-self-peptides [220, 221]. However, it is worth noting that 
T cells are also cross-reactive, having the ability to recognise multiple peptide-MHC 
complexes; the diversity of presented antigenic peptides is much larger than T cell TCR 
repertoire diversity [220, 222, 223]. Although there are multiple steps on antigen presentation-
recognition pathways (including enzymatic cleavage of a given peptide from its parent antigen, 
and transportation), peptide-MHC binding is arguably the most crucial step in T cell response 
[220, 224]. However, the likelihood and quality of the overall T cell response is dependent on 
many additional factors such as: the abundance of MHC-bound peptides; TCR recognition, 
specificity and abundance; T cell phenotypes and the presence of secondary co-stimulatory 
signals [139, 225-229]; and the genetic diversity associated with an individual’s HLA haplotype 




and the germline genes that encode their T cell receptors (TCRs) and B cell receptors (BCRs) 
[139]. 
 
1.6.1 In silico HLA II epitope prediction 
 
HLA II molecules are highly polymorphic, with thousands of known alleles belonging to each 
of the HLA genes HLA-A, HLA-B, HLA-C, HLA-DRB, HLA-DQB1 and HLA-DPB1 [230]. HLA 
II cleft is formed by two protein chains (α and β chain), encoded in one of the three loci – HLA-
DR, -DQ or -DP located in the peptide-carrying region [220, 231]. Both clefts have binding 
pockets conforming primary and secondary anchor positions on the binding peptide. Thus, 
HLA II binding cleft is open-ended, allowing longer length peptides to bind [224].  
 
It has been observed that HLA-DR binding peptides are commonly 12 amino acids long [139, 
232], although longer peptides are commonplace (up to around 30 residues) with MHC class 
II, owing to the open groove [233, 234]. In nearly all cases, the peptide binding core 
(comprising the residues within the MHC groove) consists of 9 amino acid residues [220], with 
residues outside the core contributing to binding strength and affinity [220, 232, 235]. Of the 
several thousand known HLA-DR alleles, 8 representative alleles encompass the genetic 
backgrounds of most human populations globally [139, 236]. HLA-DP and HLA-DQ alleles are 
less well characterised [139, 237]. It is suggested that some peptides can bind to several 
alleles, either by sharing common anchors across different alleles or by sharing common 
allele-specific anchors and overlapping binding cores [220].  
 
Considerable efforts have been dedicated to developing MHC class II epitope prediction 
computational methods using machine learning methods, software algorithms and data 
transformation [139]. Two pan-specific methods are available that make interpolated 
predictions for those HLA types for which insufficient binding data is available to train a 




conventional predictor, namely TEPITOPEpan [238] and NetMHCIIpan [220]. Prediction of 
class II binding is more challenging than class I, and hence typically less accurate; owing to 
the open ends of the MHC class II groove, it is necessary to predict the register of peptide 
binding as well as the strength.  Nevertheless, based on assessments by Andreatta and co-
workers [220, 239], the predictions made by recent incarnations of NetMHCIIpan are 
reasonably accurate (e.g. AUC values for DRB1*01:01, DRB1*07:01, DRB1*15:01  HLA-
DQA1*01:02-DQB1*06:02 are 0.830, 0.857, 0.831 and 0.887 respectively [239]); whereas 
individual predictions may be erroneous, the overall picture provided by a large-scale 
computational project is likely to be substantially correct. The predictive performance of the 
method is measured using the area under the receiver operating characteristics curve (AUC), 
AUC = 1 meaning perfect prediction.  
 
1.6.2 In silico HLA I epitope prediction 
 
The highly polymorphic nature of MHC I molecules contributes to different position, number 
and physiochemical properties of the binding pockets within the MHC groove. Hence different 
sets of peptides bind to different MHC molecules. HLA I cleft is formed by a single protein 
chain (α-chain) and is closed at both ends, which typically restricts the peptide length to 8-11 
amino acids, although longer peptides are possible [224, 240]. Recent studies have confirmed 
that the most abundant length of peptide binding to most MHC class I molecules consist of 9 
residues [241], although certain allelic variants are known to have a strong preference for other 
peptide length (e.g. HLA-B*18:01 has a preference for a peptide length of 8 amino acids [242], 
whereas HLA-B*44:03 has a preference for 10 or 11 amino acids [243]) [240].    
 
MHC I molecules have distinct preference for specific amino acid types within each binding 
pocket; these are known as the anchor residues of the peptide. In MHC class I, the canonical 
binding pocket positions are 2 and 9 (numbered with respect to the 9 residue locations within 




the binding core) [244]. The preference at these positions vary between alleles, for example: 
HLA-A*02:01 is associated with a preference for Leucine and either Valine or Isoleucine at 
positions 2 and 9 respectively [245]; HLA-B*08:01 is associated with a preference for positively 
charged amino acids at position 5; and HLA-A*01:01 is associated with a preference for 
Aspartic Acid at position 3 [246]. Structural limitations or interactions within the peptide may 
also contribute to presentation and ultimately recognition of the peptide-HLA complex [247]. 
 
Many computational tools have been developed to predict the epitopes binding to MHC I 
molecules, based on different approaches including similarity matrices [248], linear regression 
[249], and artificial neural networks [250-252]. NetMHCpan is available for molecules that have 
inadequate binding data [253]. Several studies [240, 254, 255] have shown NetMHCpan to be 
the most reliable tool for predicting MHC I epitopes.  
 
  








Aluminium-containing adjuvants are used to enhance the immune response and increase 
vaccine stability [256-260]. Potassium aluminium sulphate (alum) is used as an adjuvant in 
Anthrax Vaccine Precipitated (AVP). The chemical name of alum is potassium aluminium 
sulphate; however aluminium hydroxide and aluminium phosphate are often incorrectly 
termed alum [261]. During the final steps of the AVP manufacturing process, the proteins in 
the sterile CF are precipitated under gravity by adding sterile 10% w/v aluminium potassium 
sulphate solution. The pH is adjusted to 5.9-6.2 by adding hydrochloric acid. The supernatant 
is removed such that the bulk vaccine precipitate is 15x concentrated. The bulk vaccine 
concentrate is diluted with sterile saline to achieve 5x concentrated product [18]. See Figure 
12 for a flow chart of AVP manufacture from CF.  
 
In order to characterise the proteins in AVP, they need to be released or desorbed from alum 
precipitate. This chapter describes an investigation into finding a suitable desorption method 
for AVP proteins. The adsorption and desorption of proteins from aluminium adjuvants depend 
on several interactions between proteins and alum, including electrostatic forces, hydrophobic 
interactions, hydrogen bonding, van der Waals forces, ligand exchange, pH, temperature, 
ionic strength, etc. [260-266]. Historically, sodium hydroxide is used to desorb proteins from 
alum (sodium hydroxide dissolves aluminium, thereby releasing the proteins); however, this 
approach was considered potentially inappropriate on the grounds that the proteins may be 
degraded. Hence, other mild conditions using salts and surfactants were investigated for 
desorbing protein from the adjuvant in AVP. Commonly used salts for desorption include 
sodium citrate, ammonium sulphate, sodium phosphate, etc. Surfactants such as Triton X-
100, lauryl maltoside and cetylpyridinium chloride (CPC), may also be used for desorption 
[259, 260, 263, 267]. Some of these reagents were investigated for efficiency and robustness.  






Figure 12 - Process flow chart describing the process of AVP manufacture from CF 
 
2.2 Materials and Methods 
 
AVP was obtained from Porton Biopharma Ltd. Sodium hydroxide (NaOH), sodium citrate, 
succinic acid, sodium phosphate dibasic, guanidine hydrochloride, urea, ammonium sulphate, 
cetylpyridinium chloride (CPC) and ethylenediaminetetraacetic acid (EDTA) were purchased 
from Sigma Aldrich. RapiGest™ SF surfactant was purchased from Waters (Cat No: 
186001860) and ProteaseMAX™ surfactant was purchased from Promega (Cat No: V2072). 




Regenerated cellulose centrifugal concentrators were purchased from Millipore (Amicon Ultra-
0.5 Centrifugal Filter Unit, Cat No. UFC500308). Polyethersulfone (PES) membrane 
centrifugal concentrators were purchased from VWR (Vivaspin 500 3000 MW, Cat No. 512-
2838). Protein estimation Micro BCA kit was purchased from ThermoFisher (Cat No: 23235). 
MES running buffer, 4-12% bis-tris gels, and Coomassie stain were purchased from 
Invitrogen.  
 
The following nine desorption methods were assessed; each procedure was performed on 1 
vial of AVP (~620 µL).  
1. 5µL of sodium hydroxide was added. The solution was vortexed for 30 seconds until it 
turned clear. In order to neutralise the solution, 10µL of 3M sodium citrate was added 
immediately.  
2. 500µL of 250mM succinic acid, pH 3.5 was added and incubated for 30 min at room 
temperature with shaking at 40 rpm [259]. 
3. 500µL of 0.66M sodium phosphate dibasic, 3mM EDTA, pH 7.0 was added and 
incubated for 3 hours at room temperature, with shaking at 40 rpm [267]. 
4. 1mg of RapiGest™ SF surfactant was dissolved in AVP and incubated at 37°C for 24 
hours. 
5. 1mg of ProteaseMAX™ surfactant was dissolved in AVP and incubated at 37°C for 24 
hours. 
6. 500µL of 4M guanidine hydrochloride, pH 7.0 was added and incubated for 24 hours at 
room temperature, with shaking at 40 rpm. 
7. B500µL of 8M urea, pH 7.0 was added and incubated for 24 hours at room temperature, 
with shaking at 40 rpm. 
8. 500µL of 1M ammonium sulphate, 27mM CPC, pH 7.0 was added and incubated for 24 
hours at room temperature, with shaking at 40 rpm [260]. 




9. 500µL of 0.66M sodium phosphate dibasic, 3mM EDTA, pH 7.0 and 1mg of RapiGest™ 
SF surfactant was added and incubated for 3 hours at room temperature, with shaking 
at 40 rpm [267]. 
 
After the desorption process was completed, each solution was centrifuged at 14,000xg for 2 
min. The supernatants were transferred into regenerated cellulose centrifugal filter units and 
concentrated to ~100 µL by centrifuging at 14,000xg. The solutions were buffer exchanged 
into phosphate buffer saline (PBS - 100 mM Sodium Phosphate and 150 mM NaCl, pH 7.2) 5 
times, by adding 400µL of PBS each time. The final volume of each sample was ~100µL. The 
protein concentration of each sample was determined by Micro BCA kit using the 
manufacturer’s recommended procedure. Desorbed proteins were analysed by 1D gel 
electrophoresis. The samples for 1D gel electrophoresis were treated as follows: 10 µL of 4x 
LDS was added to 30µL of sample and incubated at 70°C for 10 min. 20µL of each sample 
was loaded on 4-12% bis-tris gel and run for 45 minutes at 200V using MES running buffer. 
The gel was stained using Coomassie blue stain. 
 
Further, regenerated cellulose and PES membrane centrifugal concentrators were compared 
for protein recovery. The PES filter membrane was cleaned with water prior to use according 
to the manufacturer’s recommendation.  
 
Finally, the protein concentration and protein profile of CF, supernatant and AVP were 
determined. This work was carried out on two batches of AVP. 
 
Amino acid analysis was also performed on AVP after desorption to find the protein 
concentration of desorbed proteins, and the proteins bound to alum after desorption. After 
desorption the solution was centrifuged at 14,000xg for 5 min. The supernatant (collected in a 
separate Eppendorf tube) and the pellet were sent to Alta BioSciences for amino acid analysis. 
 




2.3 Results and Discussion 
 
2.3.1 Screening of Desorption Methods 
 
As described above, several different salts and surfactants were investigated for desorption 
of AVP proteins from alum. Figure 13 shows the size-based separation of desorbed AVP 
proteins on 1D gel electrophoresis, using nine different desorption methods. The desorption 
methods with NaOH (Lane 3), EDTA (Lane 5), ammonium sulphate and CPC (Lane 11), and 
a combination of RapiGest™ SF surfactant and EDTA (Lane 12) gave good recovery of 
desorbed proteins (Figure 13). The measured protein concentration of recovered proteins from 
desorption methods with NaOH, EDTA, ammonium sulphate plus CPC and RapiGest™ SF 
surfactant plus EDTA was 27.1, 18.6, 11.6 and 18.1 µg/mL using a Micro BCA assay, 
respectively. The desorption methods with succinic acid (Lane 4), RapiGest™ SF surfactant 
(Lane 6), ProteaseMAX™ surfactant (Lane 7), guanidine hydrochloride (Lane 8) and urea 
(Lane 10) did not desorb AVP proteins from alum (Figure 13). This correlated with the Micro 
BCA assay results.  
 
Although the maximum desorption of proteins from alum in AVP was using the NaOH method, 
the higher molecular weight bands on the corresponding 1D gel (Lane 3, Figure 13) were faint 
in comparison to other methods, confirming that the harsh condition associated with NaOH 
degrades proteins. Hence, this method was not taken forward. The EDTA desorption reagent 
(Lane 5, Figure 13) gave good recovery of proteins. The desorption mechanism of EDTA is 
probably due to chelation of aluminium ions, thus enabling release of proteins from alum. The 
ammonium sulphate and CPC method (Lane 11, Figure 13) produced a pellet in the sample 
after the desorption process, hence this method was also not taken forward. The combination 
of RapiGest™ SF surfactant and EDTA (Lane 12, Figure 13) did not enhance the recovery of 
proteins in comparison to EDTA alone.  




Thus, 0.66M Sodium Phosphate Dibasic, 3mM EDTA, pH 7.0 was found to be the most 
suitable reagent for protein desorption. This mixture was further optimised, which is discussed 
in the section below. 
 
 
Figure 13 - Comparison of Desorption methods - size based separation of desorbed 
AVP proteins on 1D gel electrophoresis. Lane 1 – Molecular Weight Std; Lane 2 – Blank; 
Lane 3 – Sodium Hydroxide and Sodium Citrate method, Sodium Citrate method; Lane 4 – 
Succinic Acid method; Lane 5 – Sodium phosphate dibasic, EDTA method; Lane 6 – 
RapiGest™ SF surfactant method; Lane 7 – ProteaseMAX™ surfactant method; Lane 8 – 
Guanidine hydrochloride method; Lane 9 – Blank, Lane 10 – Urea method, Lane 11 – 
Ammonium sulphate, CPC method; Lane 12 – RapiGest™ SF surfactant, EDTA method. 
 
  




2.3.2 Optimum EDTA Concentration and pH range 
 
Further work was carried out to investigate the optimum conditions of EDTA concentration (1-
5mM) and pH range (5-9). Table 2 details the concentration of desorbed AVP proteins with 
various amounts of EDTA reagent. Figure 14A and 14B shows the size-based separation of 
desorbed AVP proteins on 1D gel electrophoresis from pH and EDTA concentration screening. 
All investigated EDTA concentrations were found to be effective; hence the least amount of 
EDTA (1mM) was found to be optimum to enable easy removal of EDTA from the final sample. 
The recovery of proteins was acceptable at pH 7, 8 and 9; whilst the recovery was low at pH 
5 and 6. Hence, the pH of 7.0 was chosen as a convenient pH that also allowed efficient 
onward processing of the samples.   
 






3 5.0 11.6 
3 6.0 14.5 
3 7.0 18.7 
3 8.0 17.2 
3 9.0 17.2 
1 7.0 18.7 
2 7.0 18.9 
3 7.0 17.4 
4 7.0 19.2 
5 7.0 17.4 
 
Table 2 – Investigation into optimum conditions for EDTA desorption reagent  – Based 
on desorbed AVP protein concentration determined using Micro BCA assay. 
  




Figure - 14A Figure - 14B 
  
 
Figure 14 - Investigation into optimum conditions for EDTA desorption reagent - Size 
based separation of desorbed AVP proteins on 1D gel electrophoresis; 14A - 
Comparison of protein recovery from 0.66M Sodium Phosphate Dibasic, 3mM EDTA pHs 5-9 
desorption; 14B - Comparison of protein recovery from 0.66M Sodium Phosphate Dibasic, 1-
5mM EDTA, pH 7.0 desorption. 
 
2.3.3 Comparison of Centrifugal Membrane Filters 
 
The recovery of proteins was found to be similar using both cellulose and PES membrane 
filters. The process time for the desorption method using a PES membrane filter was much 
longer than the regenerated cellulose membrane (data not shown here). Hence, the 
regenerated cellulose membrane centrifugal filter was found to be optimum for the 
concentration and buffer exchange process during desorption.  
 
  




2.3.4 Efficiency and Robustness of Desorption Method 
 
Finally, the protein concentration and protein profile of CF, supernatant and AVP were 
determined. Thus, the amount of protein being adsorbed onto alum precipitate, the amount of 
protein being removed in supernatant, and the amount of protein being desorbed from alum 
precipitate using the 0.66M Sodium Phosphate Dibasic, 3mM EDTA, pH 7.0 reagent were 
ascertained. Table 3 shows the total protein recovered in CF, supernatant and desorbed AVP 
proteins from two AVP batches after desorption with 0.66M Sodium Phosphate Dibasic, 3mM 
EDTA, pH 7.0 reagent, determined using Micro BCA assay. Note that the final protein 
concentration (µg/ml) has been reported based on the total volume of each batch of CF, 
supernatant and AVP. Figure 15 shows the size-based separation of proteins in CF, 





CF Batch 1 6.3 
CF Batch 2 11.3 
Supernatant Batch 1 1.6 
Supernatant Batch 2 1.8 
AVP Batch 1 14.3 
AVP Batch 2 19.8 
 
Table 3 – Average Protein concentration of CF, Supernatant and AVP after desorption 










Figure 15 - Size based separation of proteins in CF, Supernatant and Desorbed AVP 
proteins from two batches of AVP (Batch 1 (04Sep15) and 2 (17Sep15)) on 1D gel 
electrophoresis. 
 
Both protein estimation and SDS-PAGE profile show that the supernatant has some proteins 
present, suggesting that there is loss of CF proteins during the alum precipitation step during 
AVP manufacturing (Table 3, Lanes 4 and 7 in Figure 15). The final concentration of AVP is 
different to the CF concentration (despite the loss of protein in the supernatant). This 
suggested that the EDTA-based desorption method desorbs 40-60% of the proteins from alum 
in AVP (assuming that all the proteins from CF have been adsorbed onto alum precipitate).  
 
Amino acid analysis was performed on desorbed AVP proteins (desorbed using 0.66M Sodium 
Phosphate Dibasic, 3mM EDTA, pH 7.0 reagent) and pellet. However, owing to interference 
from alum and excess amino acids (which are added in the media during the manufacture of 
AVP), the amino acid analysis was not successful.  
 




The recovery of proteins from AVP using the down-selected EDTA-based desorption method 
was low. The low recovery of proteins from AVP is corroborated by similar findings by other 
groups investigating desorption of proteins from the closely-related adjuvant Alhydrogel® 
(Brenntag Biosector, Denmark) (aluminium hydroxide). Alhydrogel adjuvants are more widely 
used; hence several studies have reported the stability profile of alhydrogel based vaccines. 
Vassely et al., [259] have reported that due to chemical and physical changes in proteins 
adsorbed to alhydrogel, the desorption of proteins from alhydrogel is difficult. Another study 
has shown that the strength of the protein bound to alhydrogel increases with time, and harsh 
desorption buffer conditions are required to recover proteins [260]. This study also highlights 




Amongst all the desorption reagents and experimental conditions assessed, 0.66M Sodium 
Phosphate Dibasic, 1mM EDTA, pH 7.0 was found to be the best choice for desorbing protein 
from alum in AVP. This method was taken forward for desorbing proteins in subsequent 








3.0 PROTEOMICS STUDIES 
 
 Aims and Objectives 
 
The exact composition of AVP is not known. The main objective of this study is to identify and 
quantify proteins in AVP. Highly sensitive Mass Spectrometry (MS) based proteomics 




The Synapt G2-Si instrument from Waters Ltd was used for proteomics studies in this project. 
Peptides are separated by reverse phase chromatography and the Synapt G2-Si analyses 
mass by high resolution mass spectrometry. Electrospray Ionisation and tandem MS/MS 
(utilising triple quadrupole and time of flight (ToF) mass analysers) are used in this instrument. 
The features of each of these components have been described previously (Section 1.5.2 and 
1.5.3). Figure 16 describes the instrument schematic of Synapt G2-Si.  
 





Figure 16 – Instrument Schematic of Waters Synapt G2-Si [268] 
 
Peptide fragmentation is achieved using collision induced dissociation [82] (Section 1.5.4.1). 
Data is acquired using MSE based Data Independent Acquisition (Section 1.5.5.2), data is 
analysed on Waters PLGS platform for identifying and quantifying proteins based on label free 
Hi3 quantitation method (Section 1.5.7). 
 
As described in Chapter 2, there is variability associated with desorption process (i.e., 
desorbing proteins from alum in AVP), hence proteomic studies were performed on CF also. 
CF is essentially the same material as AVP, but the CF samples are taken from the process 
immediately prior to the addition of alum (See Section 2.1 for detailed explanation). 
 
  




 Materials & Methods 
 
3.3.1 Sample Preparation 
 
Two batches of CF and AVP were used for this work. Two biological replicates of each batch 
were prepared for LC-MS/MS analysis. The sample preparation was carried out in a class I 
cabinet, under sterile conditions. LoBind microcentrifuge tubes were used throughout the 
sample preparation (Fisher Scientific UK, Cat Nos. 10708704 and 15178344). 
 
3.3.1.1 AVP Protein Desorption 
 
A 1 ml aliquot of AVP was incubated with 1 ml of desorption buffer (0.66 M Sodium Phosphate, 
1 mM EDTA, pH 7.0) for 3 hours at room temperature, with shaking at 40 rpm. 
 
3.3.1.2 Protein Concentration and Measurement of Protein Concentration  
 
The CF and desorbed AVP samples were concentrated 20x using Amicon regenerated 
cellulose 10K centrifugal filter concentrators (UFC801096). Each solution was then buffer 
exchanged 3x into PBS (100 mM Sodium phosphate dibasic and 150 mM NaCl, pH 7.0). The 
protein concentration of all samples was measured using Micro BCA assay. 
 
3.3.1.3 Solubilisation, Reduction and Alkylation 
 
The CF and AVP concentrated samples were prepared using either urea or acetonitrile 
solubilisation protocol as detailed below: 
 
Urea Method – The sample was incubated with 12M urea in Buffer A (50 mM Ammonium 
Bicarbonate), in 1.5 ml low bind Eppendorf tube at 40°C for 10 minutes shaking, to achieve a 




final sample concentration of 8M urea (Urea – Sigma Aldrich, U5378; Ammonium Bicarbonate 
– Sigma Aldrich, 09830). The sample was centrifuged for 1 min to bring down the 
condensation droplets.  The samples were incubated with 400mM DTT (Sigma Aldrich, GE17-
1318-02) at 56°C for 30 minutes, shaking, to get final DTT concentration of 10mM. The 
samples were allowed to cool down for 5 minutes and incubated with 800mM iodoacetamide 
(IAA) (Sigma Aldrich, GERPN6302) in dark at room temperature for 30 minutes, to get IAA 
concentration of 20mM. The sample was then made up with 50mM Ammonium Bicarbonate 
solution, so that the final urea concentration was reduced from 8M to 1M.  
 
Acetonitrile Method – The concentrated sample was mixed with Buffer A (80% Acetonitrile, 
20% 50mM Trizma-HCl, 10mM CaCl2, pH 7.6) at 1:5 sample:Buffer A ratio, in 1.5 ml low bind 
Eppendorf tube at room temperature (Acetonitrile - Fisher Scientific 75-05-8; Trizma-HCL – 
Sigma Aldrich, 93363; Calcium Chloride – Sigma Aldrich, 499609). The sample was incubated 
with 400mM DTT (Sigma Aldrich, GE17-1318-02) at room temperature for 20 minutes, 
shaking, to get final DTT concentration of 10mM. The sample was incubated with 800mM 
Idoacetamide (IAA) (Sigma Aldrich, GERPN6302) in dark at room temperature for 15 minutes, 
to arrive at an IAA concentration of 10mM. 
 
Preliminary experiments showed that the urea-based solubilisation method was more 
reproducible in comparison to acetonitrile-based method; hence the sample preparation for 
the final experiments were carried out using urea-based method.   
 
3.3.1.4 Digestion Step 
 
The samples were digested by incubating with sequencing-grade modified trypsin (Promega, 
V5117) at 1:50 trypsin: protein concentration at 37°C for 16 hours, with shaking at 40 rpm. 
The samples were dried down at 35°C setting on a SpeedVac system (ThermoFisher, UK). 
 




3.3.1.5 Solid Phase Extraction Step 
 
The samples were desalted using Empore SPE Disks C18, diam. 47 mm (Sigma, 66883-U). 
The following buffers were made: Buffer A - 0.5 % Acetic acid in water (Acetic acid – Sigma 
Aldrich, 45726; LC-MS grade Water - ThermoFisher Scientific, 51140), Buffer B - 0.5% Acetic 
acid in 80% Acetonitrile (Acetonitrile - ThermoFisher Scientific, USA - 51101). Briefly, the 
freeze-dried samples were resuspended in Buffer A.  The membrane was cleaned by passing 
100% methanol (Fluka 34966), and then equilibrated with Buffer A, B and A sequentially.  The 
samples were passed through the membrane, washed with Buffer A and eluted with Buffer B. 
The samples were dried down at 35°C setting on the SpeedVac system. 
 
3.3.1.6 Spiking of the Internal Standard 
 
The samples were resuspended in Buffer A (water and 0.1% formic acid - LC-MS grade Water 
- ThermoFisher Scientific, USA – 51140; Formic acid - ThermoFisher Scientific, USA - 85178). 
An internal standard of trypsin digested BSA (Waters, UK) (125 fmole) was spiked into the 
samples.   
 
3.3.2 Reversed Phase Liquid-Chromatography Mass Spectrometry Analysis 
 
Figure 11 shows the schematic of liquid chromatography–tandem mass spectrometry (LC-
MS/MS) workflow - MSE based Data Independent Acquisition. Separation of peptides was 
performed using a 15 kpsi Waters NanoAcquity Ultra-Performance Liquid Chromatography 
system (UPLC) (Waters Corporation, USA). The following buffers were made: Buffer A - water 
and 0.1% formic acid (described above) and Buffer B - Acetonitrile and 0.1% formic acid 
(Acetonitrile - ThermoFisher Scientific, USA - 51101). A 4µL sample was injected onto a nano-
UPLC, the samples were desalted using a reverse-phase SYMMETRY C18 trap column 
(180μm internal diameter, 20mm length, 5μm particle size, Waters Corporation) at a flow rate 




of 8μL/min for 2 minutes. Peptides were separated by a linear gradient (0.3μL/min, 35°C; 97-
60% Buffer A over 60 minutes) using a custom made Acquity UPLC M-Class Peptide BEH C18 
column (130Å pore size, 75μm internal diameter, 400mm length, 1.7μm particle size, Waters 
Ltd). [Glu1]-fibrinopeptide B (GFPB, Waters, UK) was used as lockmass at 100fmol/µL. 
Lockmass solution was delivered from an auxiliary pump operating at 0.5µL/min to a reference 
sprayer sampled every 60 seconds. 
 
The nanoLC was coupled online through a nanoflow sprayer to a Q-ToF hybrid mass 
spectrometer (HDMS Synapt G2-Si; Waters, UK). The instrument was operated in positive ion 
resolution mode and tuned to a mass resolution of 19,000-24,000 (full width at half maximum). 
The ToF analyser was calibrated with fragment ions of [Glu1]-fibrinopeptide B (GFPB, Waters, 
UK) for the m/z range 175.11 to 1285.54. 
 
Data were lockmass-corrected with the monoisotopic mass of the doubly-charged precursor 
of GFPB (785.8426 m/z), post-acquisition. Accurate mass measurements were made using a 
data-independent mode  of acquisition (LC-MSE) [192]. Briefly, energy in the collision cell was 
alternated between low energy (4 eV) and high energy (energy ramp from 16-38 eV) modes 
every 0.6 seconds to acquire precursor and fragment ion spectra for retention time alignment 
and peptide sequencing during database processing. Measurements were made over a m/z 
range of 50-2000 Da with a scan time of 0.6s and an interscan delay of 0.05s. One cycle of 
MS and MSE data were acquired every 1.3s. A radio frequency was applied to the quadrupole 
mass analyser to facilitate efficient transmission of ions in 300-2000 m/z range. This ensured 
that ions below 300 m/z observed in the MSE spectrum were known to be derived from collision 









3.3.3 Database Processing 
 
Databases were searched using PLGS v3.0.2 (Waters, UK). The raw data was lockmass-
corrected, smoothed, background subtracted and deisotoped. This provided a single centroid 
accurate mass for the monoisotopic species of each peptide and respective fragment ions. 
The peptide and fragment ion retention times were aligned [269]. Data were searched against 
Uniprot complete protein database for B. anthracis Sterne 34F2 strain. Carbamidomethylation 
of Cysteine and oxidation of Methionine were specified as fixed and variable modifications, 
respectively. A maximum of two missed cleavages were allowed for semi-tryptic peptide 
identification. For peptide identification, three corresponding fragment ions were set as a 
minimum criterion whereas for protein identification a minimum of two corresponding peptide 
ions and seven fragment ions were required. Protein level FDR rate was maintained at 1% 
estimated based upon the number of proteins identified from a decoy database. Database 
search results were outputted in .csv format for further analysis. 
 
3.3.4 Protein Quantification 
 
The proteins were quantified using the Hi3 method [193]. The average MS signal for three 
most intense peptides for each protein and the internal standard was calculated. A universal 
signal response factor was calculated from the average MS signal of the internal standard 
(counts/mol of protein). The absolute protein concentration was derived by dividing the 
universal signal response factor from the average MS signal for three most intense peptides 
of a specific protein. 
 
  




 Results and Discussion 
 
3.4.1 Identification of proteins in AVP and CF 
 
Using LC-MS/MS analysis, a total of 261 and 163 proteins were matched to the B. anthracis 
proteome from AVP and CF, respectively (Figure 17). Appendix 4 and 5 lists all the proteins 
identified in CF and AVP, respectively. 138 proteins were found to be common to both AVP 











Figure 17 – Comparison of the number of proteins identified in AVP and CF by LC-
MS/MS analysis, 261 proteins were found in AVP, 163 proteins were found in CF, 138 
proteins were found common in CF and AVP (Two biological replicates and three analytical 
replicates were performed). A maximum of 11% and 19% CV was measured for two batches 
of CF and AVP, respectively (Figure adapted in Interactive Venn [270]). 
 
Two biological replicates were prepared from two batches of CF and AVP, with each sample 
analysed by LC-MS/MS in triplicate. A maximum precision of 11% and 19% CV was recorded 
for the identification of proteins in the two batches of CF and AVP respectively, including the 
AVP (261) 
CF (163) 
CF and AVP 
(138) 




biological replicates. More proteins were identified in AVP in comparison to CF, because AVP 
is five times more concentrated than CF, due to the alum precipitation step during AVP 
manufacture, as described before (Chapter 2 - Figure 12). Hence, low abundance proteins 
were identified in AVP that were not identified in CF. AVP samples had more variability in 
replicates, potentially due to the variability in the desorption process (Section 2.3.4). 
 
3.4.2 Relative quantitation of PA, LF and EF in AVP and CF 
 
PA was found to be the most abundant toxin protein in CF and AVP, followed by LF and EF 
(Figure 18). For CF and AVP, PA accounted for 65% and 64% of total protein respectively, LF 




Figure 18 – Composition of AVP - PA was the principle component of the vaccine (65%), LF 
was found to be 8% and EF was found to be 3%, 258 proteins were found in lower 
abundances, comprising the other 25% (Figure adapted in Interactive Venn [270]). 
 
Repeatability for relative quantitation of PA, LF and EF proteins in CF and AVP was good, a 









analysis (Figure 19). Several Hi3 quantitation studies have reported similar CVs in complex 












Figure 19 – Relative Quantitation of PA, LF and EF in two batches of CF and AVP. Error 
bars represent ± 1 SD about the mean. Two biological replicates and three analytical replicates 
were performed. 
 
3.4.3 Absolute quantitation of PA, LF and EF in AVP and CF 
 
As described before, PA was found to be the most abundant protein in CF and AVP, followed 
by LF, Enolase, PX01-90, EF, 60kD Chaperonin, alcohol dehydrogenase and 
phosphoglycerate kinase. PA was measured to be 615 and 2831 ng/mL in CF and AVP; LF 
was measured to be 52 and 345 ng/mL in CF and AVP; EF was measured to be 30 and 119 

































Figure 20 – Top 8 most abundant proteins in CF and AVP (PA – Protective Antigen, LF – 
Lethal Factor, Eno – Enolase, PX01-90, EF – Edema Factor, Chap – Chaperonin 60, AD – 
Alcohol Dehydrogenae, PGK – Phosphoglycerate Kinase). Error bars represent ± 1 SD about 
the mean. Two biological replicates and three analytical replicates were performed. 
 
Previously, the average concentration of PA and LF was reported to be 3710 and 990 ng/ml, 
respectively, in culture supernatant from AVP production, determined by ELISA [18]. Although 
Hi3 label-free quantitation is deemed reliable for absolute quantitation of proteins [193, 195], 
absolute quantitation was not possible for CF and AVP. The quantitation data for PA and LF 
using ELISA is significantly different from LC-MS/MS data in the present study. Sample 
preparation steps involving desorption, sample concentration using centrifugal filters and solid 
phase extraction steps using C18 disks potentially resulted in loss of proteins. Calculations 
show that only 20% of the sample was recovered from LC-MS/MS experiment, based on the 
total protein estimation by Micro BCA assay. Sample manipulations in standard polypropylene 
Eppendorfs also resulted in loss of protein, hence lo-bind tubes were used. 
 




Nevertheless, a maximum of 25% CV was measured for the quantification of abundant 
proteins in two batches of CF (including biological replicates). The repeatability of AVP 
biological replicates was poor and a CV of 15% was measured for PA (the most abundant 
protein in AVP), and approximately 40% for less abundant proteins. AVP samples had more 
variability in biological replicates, possibly due to the variability in the desorption process. The 
repeatability of the triplicate analysis of each AVP sample was <20%. For accurate absolute 
quantitation of proteins in CF and AVP, sample preparation designed to minimise the loss of 
protein (i.e. without desorption, concentration step and solid phase extraction) would be 
required. However, this proved unfeasible, as further investigation revealed that CF contains 





A total of 138 proteins were identified in AVP and CF using proteomic LC-MS/MS analysis. 
PA (65%), LF (8%) and EF (3%) were found to be the most abundant proteins in AVP, using 
DIA based Hi3 label free quantitation. A maximum of 18% CV was measured for the relative 
quantitation of eight abundant proteins analysed in AVP, including biological and technical 
replicates. The study highlights the difficulty in measuring absolute quantity of proteins in alum 








4.0 COMPUTATIONAL STUDIES 
 
4.1 Aims and Objectives 
 
Computational studies will be carried out to predict CD4+ and CD8+ peptide-MHC binding for 
the eight most abundant proteins of AVP (Section 3.4.3 – Figure 20). The differences in 
peptide-MHC binding affinity were investigated across a selection of HLA alleles that provides 




MHC II epitopes were predicted using NetMHCIIpan 3.2 [239] for the eight most abundant 
proteins in AVP (Section 3.4.3, Figure 20) and across multiple HLA alleles in order to assess 
the impact of allelic differences in human populations. As described previously (Section 1.6.1), 
the length of the peptide binding to HLA II molecules can vary between 9-30 amino acids. 
However, a length of 15 amino acids is widely used in both experimental and computational 
studies [272]. 
 
Given the reasonable assumptions that a) epitope binding affinity is correlated with the 
strength of the immune response, and b) a larger proportion of peptides predicted to bind with 
moderate to high affinity (≤500 nM) are likely to be true epitopes than those predicted to bind 
with low affinity (>500 nM and ≤5000 nM), only predicted epitopes with high and intermediate 
binding affinity were taken forward for analysis. Two IC50 binding thresholds advocated by the 
Immune Epitope Database (IEDB) [273], ≤50 nM and ≤500 nM, were adopted for predicted 
epitopes with high binding affinities (strong binders) and intermediate binding affinities 
(medium binders), respectively. 
 




NetMHCIIpan is not completely accurate and may be prone to either over- and under-
prediction in specific cases. It has been observed, for example, that standard computational 
tools predict a subset of experimentally-verified immunodominant peptides to bind too weakly 
to form epitopes [274]. However, in the context of this study computational methods are of 
sufficient accuracy to give us broad insights covering multiple antigens and many HLA alleles 
– a combination that poses an unsolved challenge to experimental approaches. 
 
MHC I epitopes were predicted using NetMHCpan 3.0 [250, 253] for the eight most abundant 
proteins in AVP and across multiple HLA alleles in order to assess the impact of allelic 
differences in human populations. As described previously (Section 1.6.2), the length of the 
peptide binding to HLA I molecule can vary from 8-11 amino acids. However, the length of 9 
amino acids has been observed to be the most abundant with most HLA alleles in recent, 
high-throughput immunopeptidome studies thought to be optimal and was used in this study 
[241, 275]. Rather than an absolute binding threshold, NetMHCpan adopts a relative ranking 
approach, with predicted affinity compared to those of a large set of random natural peptides; 
peptides with a %rank <0.5 are deemed strong binders. Only strong binders were taken 




4.3.1 MHC II epitope prediction 
 
MHC class II predictions were carried out to identify the epitopes found in the eight most 
abundant proteins of AVP (Section 3.4.3 - Figure 20), using NetMHCIIpan 3.2 [239]. A set of 
25 HLA class II alleles were selected that provide a global population coverage of over 99% 
[231]. Python scripts were written to enable automation (See Appendix 1). Binding affinities of 
peptides with IC50 ≤50 nM cut off and ≤500 nM cut off were used to select strong and medium 
binding epitopes, respectively [273].   




4.3.2 B. anthracis strain data 
 
The PA, LF and EF protein sequences from 33 known B. anthracis strains were analysed for 
in order to identify mutations using the MegAlign software [276]. The list of all B. anthracis 
strains evaluated in the study are detailed in Appendix 3; genomic sequences for these strains 
were obtained from the NCBI database [277]. Substitutions were then analysed with respect 
to MHC class II antigen presentation to assess whether they changed the immunogenic 
properties of these proteins. 
 
4.3.3 MHC I epitope prediction 
 
MHC class I predictions were carried out to identify 9-mer epitopes in the eight most abundant 
proteins of AVP (Section 3.3 – Figure 20) using NetMHCpan 3.0 [250, 253]. The choice of 
HLA-I alleles (Table 4) was based on a meta-analysis of HLA allele frequency data published 
by Solberg and co-workers [278, 279]. From each of the HLA-A, -B and -C genes, 10 high 
frequency alleles were selected. Epitopes were additionally predicted for comparatively low-
frequency HLA-B alleles (e.g. HLA-B*27:05 and HLA-B*39:05) that are considered 
representatives of so-called HLA supertypes [278, 279]. Python scripts were written to enable 
automation (See Appendix 1). Binding affinities of peptides with %Rank threshold of 0.5 was 
used to select strong binding epitopes.  
  









1 HLA-A*01:01 0.04843 
2 HLA-A*02:01 0.15284 
3 HLA-A*03:01 0.04272 
4 HLA-A*24:02 0.18816 
5 HLA-A*11:01 0.11661 
6 HLA-A*31:01 0.04093 
7 HLA-A*33:03 0.04081 
8 HLA-A*02:06 0.03469 
9 HLA-A*26:01 0.03354 
10 HLA-A*30:01 0.02505 
11 HLA-B*35:01 0.05466 
12 HLA-B*51:01 0.05222 
13 HLA-B*40:01 0.05120 
14 HLA-B*44:03 0.04473 
15 HLA-B*07:02 0.04105 
16 HLA-B*15:01 0.03431 
17 HLA-B*08:01 0.02960 
18 HLA-B*58:01 0.0289 
19 HLA-B*27:05 0.01236 
20 HLA-B*39:05 0.00455 
21 HLA-C*07:02 0.13101 
22 HLA-C*04:01 0.11177 
23 HLA-C*03:04 0.09132 
24 HLA-C*01:02 0.08481 
25 HLA-C*07:01 0.06887 
26 HLA-C*06:02 0.06160 
27 HLA-C*03:03 0.05580 
28 HLA-C*08:01 0.04522 
29 HLA-C*15:02 0.03362 
30 HLA-C*12:02 0.03191 
 
Table 4 - MHC I alleles used in this study and their frequencies (Adapted from Solberg et 
al., [279]) 




4.4 Results and Discussion 
 
4.4.1 MHC II epitope prediction 
 
The number of strong and medium-plus-strong binders for eight AVP proteins and 25 HLA 
alleles are shown in Tables 5 and 6, respectively.  
 
Before interpreting these results, it is important to note that one needs to be cautious, as 
binding affinity between peptide and MHC molecule is just one of the many factors contributing 
to the T cell response. Whereas peptide-MHC binding affinity can be predicted with reasonable 
accuracy, in the present context there is no information about other important factors such as 
T cell precursor frequency [280-282] and the breadth of the T cell response [283]. The 
emerging picture from many independent research studies is a highly complex one; hence 
within a given individual, specific epitopes may be protective whereas others may have a 
negative impact, for example by blocking or slowing down the T cell response [284, 285], or 
by inducing autoimmunity [280, 285, 286]. In principle and presumably in practice, the same 
epitope may lead to different outcomes in different individuals.  
 
Bearing these points in mind, there are nevertheless cautious but potentially important 
conclusions that can be drawn from the MHC II-peptide binding prediction. In interpreting these 
results, the confidence that a given antigen is likely to be protective with respect to a given 
HLA allele depends on the number of predicted epitopes, and in particular the number of 
epitopes predicted to be at least medium binders. If the number of medium-plus-strong 
epitopes is low, there is a greater possibility that an individual will lack TCRs capable of binding 








HLA II Alleles 
No. of strong binding epitopes 
PA LF EF PX01 Chap. AD Eno PGK 
HLA-DPA1*01:03-DPB1*02:01 3 6 12 9 0 0 0 0 
HLA-DPA1*01:03-DPB1*04:01 0 5 4 9 0 0 0 0 
HLA-DPA1*02:01-DPB1*05:01 0 0 0 0 0 0 0 0 
HLA-DPA1*03:01-DPB1*04:02 0 5 0 0 0 0 0 0 
HLA-DQA1*01:01-DQB1*05:01 0 0 0 0 0 0 0 0 
HLA-DQA1*01:02-DQB1*06:02 0 0 0 0 3 0 5 0 
HLA-DPA1*02:01-DPB1*01:01 0 5 0 0 0 0 0 0 
HLA-DQA1*03:01-DQB1*03:02 0 0 0 0 0 0 0 0 
HLA-DQA1*04:01-DQB1*04:02 0 0 0 0 0 0 0 0 
HLA-DQA1*05:01-DQB1*02:01 0 0 0 0 0 0 0 0 
HLA-DQA1*05:01-DQB1*0301 5 0 0 0 12 11 7 19 
HLA-DRB1*01:01 44 100 101 27 42 20 43 49 
HLA-DRB1*03:01 7 21 0 0 4 2 0 0 
HLA-DRB1*04:01 1 3 10 0 0 0 3 0 
HLA-DRB1*04:04 5 0 5 4 0 1 0 5 
HLA-DRB1*04:05 0 0 12 0 0 0 0 0 
HLA-DRB1*07:01 15 33 28 7 0 2 4 12 
HLA-DRB1*08:02 0 0 0 0 0 0 0 0 
HLA-DRB1*09:01 0 18 14 4 3 1 4 11 
HLA-DRB1*11:01 6 5 20 2 0 0 6 4 
HLA-DRB1*13:02 32 36 30 9 10 10 8 11 
HLA-DRB1*15:01 5 30 7 7 0 0 0 0 
HLA-DRB3*01:01 4 20 0 0 0 2 0 0 
HLA-DRB4*01:01 6 2 0 0 0 0 0 0 
HLA-DRB5*01:01 7 25 28 11 0 0 14 14 
Total No. of Epitopes 140 314 271 89 74 49 94 125 
 
Table 5 - Predicted number of strong binding MHC II epitopes, derived using 
NetMHCIIpan (IC50 cut-off of ≤50 nM). 
  




HLA II Alleles 
No. of medium-plus-strong binding epitopes 
PA LF EF PX01 Chap. AD Eno PGK 
HLA-DPA1*01:03-DPB1*02:01 55 118 146 67 13 2 34 60 
HLA-DPA1*01:03-DPB1*04:01 41 88 68 52 5 0 23 25 
HLA-DPA1*02:01-DPB1*05:01 14 32 50 26 0 0 4 3 
HLA-DPA1*03:01-DPB1*04:02 33 61 48 44 3 0 17 14 
HLA-DQA1*01:01-DQB1*05:01 22 28 40 27 0 0 11 13 
HLA-DQA1*01:02-DQB1*06:02 58 40 34 34 137 63 63 62 
HLA-DPA1*02:01-DPB1*01:01 50 121 130 66 12 0 35 57 
HLA-DQA1*03:01-DQB1*03:02 5 2 0 0 15 0 0 4 
HLA-DQA1*04:01-DQB1*04:02 5 4 3 0 29 0 7 4 
HLA-DQA1*05:01-DQB1*02:01 29 56 54 20 75 23 65 35 
HLA-DQA1*05:01-DQB1*0301 89 48 58 39 197 114 121 111 
HLA-DRB1*01:01 346 398 358 263 299 165 188 225 
HLA-DRB1*03:01 107 124 53 23 45 49 30 41 
HLA-DRB1*04:01 139 211 172 86 64 33 67 71 
HLA-DRB1*04:04 171 223 189 121 124 57 89 105 
HLA-DRB1*04:05 112 207 172 89 39 24 51 69 
HLA-DRB1*07:01 195 235 205 105 113 90 100 106 
HLA-DRB1*08:02 75 111 112 34 75 28 56 43 
HLA-DRB1*09:01 169 214 195 74 134 97 121 115 
HLA-DRB1*11:01 128 202 221 114 89 33 79 89 
HLA-DRB1*13:02 244 277 224 147 122 84 92 102 
HLA-DRB1*15:01 150 214 190 112 52 41 73 96 
HLA-DRB3*01:01 82 130 86 31 31 32 27 34 
HLA-DRB4*01:01 156 236 195 158 123 45 72 100 
HLA-DRB5*01:01 176 216 258 134 115 55 86 108 
Total No. of Epitopes 2651 3596 3261 1866 1911 1035 1511 1692 
 
Table 6 - Predicted number of medium-plus-strong binding MHC II epitopes, derived 
using NetMHCIIpan (IC50 cut-off of ≤500 nM). 
 
  




The NetMHCIIpan tool predicted that peptides from all eight proteins are likely to be presented 
to T cells, however the number of such peptides varied considerably between different HLA 
alleles (Tables 1 and 2). The “core” vaccine components PA, LF and EF were associated with 
at least 5 medium-plus-strong class II epitopes with the notable exceptions of common HLA-
DQ alleles HLA-DQA1*0301-DQB1*0302 and HLA-DQA1*0401-DQB1*0402. In both these 
cases, a much higher number of medium-plus-strong epitopes was associated with the 60 kDa 
Chaperonin protein (15 and 29 epitopes respectively).  
 
Given that individuals have multiple class II HLA alleles, the data in Table 6 suggests that 
most individuals vaccinated with AVP have the potential to undergo a protective T cell 
response, although the proteins involved may vary between individuals. From this analysis, it 
appears that the efficacy of PA alone is by no means guaranteed and that the presence of 
additional proteins enhances the prospects that AVP affords broad protection.  
 
4.4.2 Efficacy of AVP against different B. anthracis strains 
 
Multiple sequence alignments of PA, LF and EF protein sequences from 33 known B. anthracis 
strains were generated. These alignments revealed 3, 4 and 6 single amino acid differences 
for PA, LF and EF respectively between the vaccine (Sterne) strain and the other strains. 
NetMHCIIpan was used to make predictions for all 15-mers spanning each of these 
substitutions. The results are summarised in Table 7. 
 
None of the predictions in Table 7 were for strong binding epitopes (≤50 nM binding affinity), 
and the numbers of predicted changes is very small compared to the total number of predicted 
epitopes for each of these proteins (Table 6). Nevertheless, there remains a small possibility 
that an individual’s immunodominant vaccine response, induced by the Sterne strain, may be 
comparatively less effective against a different strain if one or more critical epitopes are absent 
or different in that strain.   

















PA I433V HYU01 9 0 5 
PA P565S 
CDC 684, SK-102, Vollum 
1B, Vollum 
10 12 9 
PA A600V 
BA1015, Canadian Bison, 
CDC 684, isolate IT Carb1-
6241, isolate IT Carb3-6254, 
PAK-1, RA3, SK-102, 
Turkey32, V770-NP-1R, 
Vollum 1B, Vollum, Pollino, 
P.NO2, Larissa, HYU01, 
H9401, A1144 
18 5 11 
LFK155X P.NO2 4 9 13 
LF S299A 
1C3, 4NS, A16, A16R, 
A0248, A1144, A2012, Ames 
0462, Ames BA1004, 
BA1015, Canadian Bison, 
CDC 684, H9401, Larissa, 
Ohio, P.NO2, Pak-1, Pollino, 
Shikan, SK-102, Stendal, 
Turkey 32, V770-NP-1R, 
VCM1168, Vollum 1B, 
Vollum 
0 4 16 
LF S299T 
BA1035, HYU01, RA3, 
SVA11 
3 0 12 
LF Q346E H9401 0 5 1 
LF E709G 
BA1035, HYU01, P.NO2, 
RA3, SVA11 
0 0 0 
EF D84G A16R 0 40 1 
EF D180G 
BA1035, HYU01, RA3, 
SVA11 
22 16 19 
EF I318T 
BA1035, HYU01, RA3, 
SVA11 
10 0 0 
EF G352V A16R 0 0 0 
EF E443D Canadian Bison 0 0 0 
 
1The number of HLA-II alleles for which a Sterne strain epitope in Table 6 is predicted to be a non-
binder in a non-Sterne strain 
2The number of HLA-II alleles for which an epitope is predicted with a non-Sterne strains that is not 
predicted to be an epitope with the Sterne strain 
3The number of HLA-II alleles for which a Sterne strain epitope is predicted to present a different epitope 
in non-Sterne strains (i.e. the epitope has a different TCR-facing amino-acid residue). 
 
Table 7 - Predicted medium-plus-strong binding MHC II epitope differences between the 
Sterne strain and other B. anthracis strains, derived using NetMHCIIpan (IC50 cut-off of 
≤500 nM). 




4.4.3 MHC I epitope prediction 
 
Table 8 details the predicted number of strong binding MHC I epitopes for each of the analysed 
eight proteins in AVP. The NetMHCpan tool predicted that the peptides from all eight proteins 
are likely to be presented to T cells, with the largest number of strong binding MHC I epitopes 
observed in PA, LF and EF across different alleles. However, when the number of epitopes 
were normalised relative to amino acid length, these proteins did not have statistically higher 
number of epitopes in comparison to other proteins. This analysis suggests that many proteins 
in AVP have the potential to induce a CD8+ T cell response 
  




HLA I Alleles 
No. of strong binding epitopes 
PA LF EF PX01 Chap. AD Eno PGK 
HLA-A*2402 12 11 13 7 0 0 1 3 
HLA-A*0201 7 9 13 3 6 2 6 12 
HLA-A*1101 14 12 16 17 11 6 7 7 
HLA-A*0101 13 17 34 2 0 2 11 2 
HLA-A*0301 14 18 16 13 9 4 9 5 
HLA-A*3101 9 4 7 4 2 3 6 3 
HLA-A*3303 8 5 13 7 1 4 4 2 
HLA-A*0206 4 9 9 2 7 3 4 10 
HLA-A*2601 13 20 16 9 3 3 13 6 
HLA-A*3001 10 6 16 8 12 4 6 11 
HLA-B*3501 10 10 17 5 6 1 3 9 
HLA-B*5101 13 5 6 2 0 4 5 6 
HLA-B*4001 10 16 11 10 12 3 8 14 
HLA-B*4403 15 21 21 13 8 5 11 4 
HLA-B*0702 9 3 8 4 10 6 1 11 
HLA-B*1501 9 9 13 3 5 2 6 2 
HLA-B*0801 7 7 4 7 5 0 2 3 
HLA-B*5801 11 5 13 2 1 1 0 2 
HLA-B*2705 9 7 5 2 3 1 3 5 
HLA-B*3905 6 10 8 11 1 0 8 4 
HLA-C*0702 8 10 18 7 0 1 4 2 
HLA-C*0401 10 9 12 5 3 2 7 6 
HLA-C*0304 14 8 10 6 12 1 4 9 
HLA-C*0102 10 12 16 2 5 1 4 8 
HLA-C*0701 10 11 7 12 0 1 4 3 
HLA-C*0602 11 11 9 9 1 1 5 2 
HLA-C*0303 14 8 10 6 12 1 4 9 
HLA-C*0801 13 12 12 7 5 2 4 10 
HLA-C*1502 11 13 10 3 4 3 3 9 
HLA-C*1202 11 14 14 5 5 3 3 11 
Total No. of Epitopes 315 312 377 193 149 70 156 190 
Normalised with 
sequence length 
41 41 49 25 20 9 20 25 
No. of Alleles 13 15 12 10 6 8 9 8 
 
Table 8 - Predicted number of strong binding MHC I epitopes, derived using NetMHCIpan 
(Rank cut-off of 0.5). 






NetMHCIIpan predicted that peptides from all eight abundant proteins are likely to be 
presented to T cells, a pre-requisite for protection; however, the number of such peptides 
varied considerably for different HLA alleles. This suggests that the effectiveness of AVP 
within humans does not depend on PA alone; other B. anthracis proteins in AVP may be 
important for individuals with specific HLA allele combinations. Further, in spite of differences 
in the sequences of key antigenic proteins from different B. anthracis strains, computational 
analysis suggested that these do not affect the protection that AVP affords to strains other 
than the vaccine’s source strain. Nevertheless, there remains a small possibility that an 
individual’s immunodominant vaccine response, induced by the Sterne strain, may be 
comparatively ineffective against a different strain if one or more critical epitopes are absent 
or different in that strain. Further, NetMHCpan predicted that not only PA, LF and EF, but other 
B. anthracis proteins in AVP have a strong likelihood of epitope presentation across various 
HLA alleles and may contribute to triggering CD8+ T cell response. This corroborates with 
current knowledge and understanding on anthrax toxins and the way in which LT and ET 
supresses the host immune system by impairing the functions of several phagocytes, T cells 
and B cells [28, 81], as described previously in Section 1.3.3.  
 
  




5.0 IN VITRO STUDIES 
 
5.1 Aims and Objectives 
 
A small proof-of-concept study was designed to characterise the immune response from PA 
and LF in human AVP vaccinees. The aim of this study was to investigate the cellular and 
humoral (antibody) response in AVP vaccinees, including impact of genetic diversity and 
corroborate findings with computational studies. This study evaluated the T cell response by 
measuring IFNy and IL10 cytokine levels when stimulated with rPA (recombinant PA) and rLF 




PA is thought to be the primary immunogen in both AVP and AVA. As described previously 
(Section 3.3.2, Figure 18), AVP contains at least 138 proteins, including PA (65%) and LF 
(8%). LF is the next most abundant protein in AVP after PA. Computational studies (Section 
4.4.1, Table 5 and 6) suggest that peptides from LF are likely to be presented to T cells by 
MHC molecules encoded by HLA alleles that provide broad coverage of the global human 
populations. In fact, the overall number of strong and strong-medium binding epitopes for LF 
is predicted to be higher in comparison to PA. This suggests that LF is an important 
immunogen in AVP. Previous studies have also proposed that LF enhances PA-specific 
antibody response [6, 8, 9], and that anti-LF antibodies are protective [3, 10, 11]. Ingram et 
al., [169] have reported that LF shows a strong long-lasting CD4+ T cell response in both AVP 
vaccinees and cutaneous Anthrax patients.  
 
Hence, this study was designed to characterise the cellular and humoral response from PA 
and LF in AVP vaccinees. The cellular immune (T cell) response was measured by stimulating 
peripheral blood mononuclear cells (PBMCs) with rPA and rLF and measuring the release of 




IFNy and IL10 cytokines. The humoral immunity (antibody response) was determined by 
measuring anti-PA antibodies, anti-LF antibodies and TNA levels. Further, the aim of the study 
was to correlate the T cell response with antibody response, as well as corroborate at least a 
subset of the computational findings discussed in Chapter 4.  
 
IFNγ cytokine was selected in this study as it is thought to induce a Th1 immune response by 
regulating chemotaxis, promoting phagocytosis and upregulating antigen presentation. IFNγ 
is secreted by NK cells and T lymphocytes and is required for optimal antibody-mediated 
protection against infection [287]. It is thought to play an important role in mediating the cellular 
immune response against Anthrax [288-290]. IL-10 cytokine levels were also measured in this 
study, as it is an important immunoregulator that inhibits the excessive Th1 and CD8+ T cell 
responses that are associated with potentially dangerous proinflammatory responses during 
infection [291]. It is mainly secreted by helper T cells type 2 (Th2), regulatory T cells, 
monocytes, some dendritic cells, activated macrophages and granulocytes [291, 292].  
 
5.3 Materials and methods 
 
5.3.1 Blood collection 
 
Eight AVP-vaccinated volunteers and two non-vaccinated control volunteers based at PBL, 
Porton Down, participated in this study, in the context of a study protocol (Ref: R&D 325) 
approved by the PHE Independent Ethics Committee, UK. The subjects were all adults aged 
over 18 years and all provided written, informed consent. A total of 29 ml of blood was collected 
from each volunteer. Although volunteers were not recruited based on their vaccination dates, 
details of their AVP vaccination history were recorded. 
 
From each volunteer, 10 ml x 2 blood was collected in sodium heparin plasma tubes (Midmeds 
Cat No. MD368480), 4 ml in K2EDTA tubes (Midmeds Cat No. MD367839) and 5 ml in clot activator 




coated tubes (Midmeds Cat No. MD367954). Blood collection was performed by a PBL 
Occupational Health phlebotomist nurse. Each donor blood sample was labelled 1-10 
anonymously and stored at room temperature. Samples 5 and 10 were blood collected from 
control individuals (i.e. individuals who had never been vaccinated with AVP). 
 
On the same day as blood collection, PBMCs were isolated from 20 ml of volunteer blood 
collected in sodium heparin plasma tubes. The work was performed in Culture Collections labs 
at PHE, Porton Down.  Each sample was treated as follows: Blood was transferred from each 
donor into 50 ml falcon tube and was made up to 40 ml with RPMI-1640 medium (Sigma 
R8758). To prepare the Accuspin tubes 50 ml (Sigma A2055), the tubes were filled with 15 ml 
of Ficoll Plaque Plus (Sigma GE17-1440-02) and spun at 1000g for 2 min. Blood was then 
transferred to the Accuspin tubes and spun at 1000g for 20 min for PBMC separation. The 
white layer (PBMCs) was recovered and transferred to a fresh 50 ml falcon tube. The solution 
was then made up to 40 ml using RPMI-1640 medium. The sample was centrifuged at 300g 
for 10 min. The supernatant was discarded, and the pellet was recovered with 15 ml of RPMI-
1640 medium. Cell counting was done using NucleoCounter (Chemometec, UK). The sample 
was again spun at 300g for 5 min. The supernatant was discarded, and the pellet was diluted 
in 5 ml of chilled Foetal bovine serum + 10% DMSO. 5 x 1 ml sample was transferred to 
cryovials and transferred to a Mr. Frosty container, before transfer into -80°C.  
 
5.3.2 HLA tissue typing 
 
HLA tissue typing analysis was contracted to Proimmune Ltd, UK. Blood (4 ml) was collected 
in K2EDTA tubes (Midmeds, UK) and stored at -80°C. The MHC II alleles for each donor for the 
6x loci (2 x DRB1, 2 x DQB1 and 2 x DPB1) were reported. 
 
  




5.3.3 Anti-PA and anti-LF IgG ELISA assay 
 
Blood (5 ml) that was collected in clot activator coated tubes (Midmeds, UK) was centrifuged 
at 2,000 x g for 10 minutes. The supernatant was recovered and stored at -80°C for anti-PA 
and anti-LF IgG ELISA and TNA assay.  
 
These tests were performed by the Medical Interventions Group (MIG) at Public Health 
England (PHE), Porton Down. Briefly, 96-well plates (NUNC flat bottomed wells, 
ThermoFisher, UK) were coated overnight with either purified rPA (E. coli-derived, PHE 
Porton) or rLF (B. anthracis-derived, PHE Porton), before the addition of serial-diluted human 
serum samples and reference (IAG/AIQC/04, PHE Porton). The reference serum was 
prepared by plasma conversion of plasma collected from AVP-vaccinated individuals (not 
originating from this study). Anti-human IgG Fcγ-specific antibody conjugated to Alkaline 
Phosphatase (Jackson Immunoresearch) was used to produce a colorimetric response 
proportional to the amount of PA or LF specific antibody when substrate (AP Yellow, BioFX & 
surmodics) was added. Plates were read using a Versamax plate reader with SoftMax Pro 5.2 
analysis software (Molecular Devices). Each sample was assigned a titre against a 5PL 
human sera reference curve. The reference serum was assigned values of 960U/ml (PA) and 
500 U/ml (LF) based on the mean ED50 value of multiple runs on previous occasions (not 
included in this study). 
 
  




5.3.4 Toxin neutralising assay  
 
Sera were serially diluted and incubated with Lethal Toxin (PHE Porton) at a controlled 
concentration. This was transferred to 96-well plates seeded with a mouse macrophage cell 
line (J774A.1, ECACC 9105151) known to be sensitive to Anthrax toxin-mediated cytotoxicity. 
Cell survival was assessed through uptake of methylthiazolyldiphenyl-tetrazolium bromide 
(MTT, Sigma, UK) by surviving cells; this provided a colorimetric readout of survival. Plates 
were read using a Versamax plate reader with SoftMax Pro 5.2 analysis software (Molecular 
Devices, US). Sample ED50 values (the dilution of serum required for a 50% reduction in 
cytotoxicity) were compared to a reference serum (IAG/AIQC/07, PHE Porton), which allows 
an NF50 value to be calculated for each sample. The reference serum was prepared by plasma 
conversion of plasma collected from AVP-vaccinated individuals (not originating from this 
study). The ED50 of the reference and samples and NF50 of the samples are reported. 
 
5.3.5 rPA and rLF peptide library 
 
rPA (5.5 mg/mL) and rLF (2 mg/mL) were acquired from Porton Biopharma Ltd. Peptides were 
acquired from Pepscan, Netherlands. PA and LF peptides (15mers) of ≥90% purity were 
synthesized (Table 9). These peptides were selected as they were previously described as 
immunodominant epitopes. The peptides were delivered in lyophilised form. The complete list 









Antigen Peptides Reference 
PA 
397-411, 408-422, 501-515, 
512-526, 709-723, 720-734 
[218] 
177-191, 188-202, 253-267, 




570-584, 581-595, 650-664, 
661-675, 672-686, 683-697, 
710-724, 721-735 
[169] 




*Peptides LF 464-478 and LF 475-489 could not be synthesised to required purity levels. 
Table 9 – rPA and rLF Peptide library 
 
5.3.6 Measurement of cytokine response 
 
IFNy and IL10 cytokine response in PBMCs to various AVP protein stimulants was 
investigated for each sample. These tests were performed by Cisbio Bioassays. Human IFNy 
assay Kit (Cat No. 62HIFNGPEG) and Human IL10 Assay Kit (Cat No. 62HIL10PEG) ELISA 
based kits were used for the measurement of cytokines. Prior to the cytokine assays, the 
PBMCs were observed under the microscope to ensure that the cells were alive and healthy. 
Additionally, the cytokine response in the PBMCs was investigated with IMA/Ionomycin as a 
positive control to ensure that the PBMCs were functional.  
 
The peptides were dissolved in 5-30µL of 10% DMSO based on solubility. 100µL of water was 
added, then the solution was made up to 1 ml using RPMI-1640 working buffer. Thus, the final 
concentration of the peptide was 2 mg/ml. Once the peptides were reconstituted, the vials 
were added together as described below. Since it was not possible to test each peptide 
individually due to the limitation with volunteer PBMCs samples, peptide mix were made as 




follows, so that cytokine response from certain part of PA, LF or EF sequence could be tested: 
PA mix 1 - 253-267, 264-278, 275-289, PA mix 2 - 633-647, 644-658, 655-669, PA mix 3 - 
397-411, 408-422, PA mix 4 - 501-515, 512-526, PA mix 5 - 709-723, 720-734, LF mix 1 - 
570-584, 581-595, LF mix 2 - 650-664, 661-675, LF mix 3 - 672-686, 683-697, LF mix 4 - 710-
724, 721-735. The final concentration of each mix was 2 mg/mL.  
 
PBMCs (480K cells/well) were stimulated with 10 µg/ml of rPA, rLF or peptide mixes for 72 
hours. Supernatant (50µL) was then transferred to new wells and cytokine levels were 
measured according to the instructions in the Cisbio kits. The cell count was underestimated 
for these experiments; the live cell count was decreased significantly post cryopreservation. 
Further, significantly higher cell count of PBMCs was required in the assay than anticipated, 
as was determined during preliminary experiments. Hence, the number of samples that could 
be tested for each stimulant varied, depending on the live cell count. Appendix 6 details the 
grid of samples and stimulants tested for cytokine response.  
 
5.4 Results and Discussion 
 
5.4.1 HLA tissue typing 
 
The HLA types and immunisation history of volunteers are shown in Table 10.   
  


























*03:02:01 *03:01:01 *03:01:01 *03:01:01 
3 2014, 2016 *15:01:01 *04:01:01 *06:02:01 *03:01:01 *04:01:01 *04:01:01 
4 1999, 2016 *04:01:01 *11:02:01 *03:01:01 *03:19:01 *04:01:01 *04:01:01 
5A N/A *15:01:01 *15:01:01 *06:02:01 *06:02:01 *02:01 *04:01:01 





*15:01:01 *11:04:01 *06:02:01 *03:01:01 *04:01:01 *11:01:01 
8 2014, 2016 *04:08:01 *07:01/79 *03:03:02 *03:01:01 *04:01:01 *04:01:01 
9 2016, N/A *03:01:01 *04:01:01 *02:01:01 *03:01:01 *01:01:01 *20:01:01 
10A N/A *07:01/79 *07:01/79 *02:02:01 *02:02:01 *17:01:01 *17:01:01 
ASamples from control volunteer 
Table 10 – Volunteer HLA types and immunisation history 
 
5.4.2 Anti-PA antibody, anti-LF antibody and TNA levels 
 
The antibody titres measured in sera from volunteers is detailed in Table 11 and Figure 21. 
As expected, the antibody titre and TNA levels in the control samples were below the detection 
limit (Table 11). On the other hand, the antibody titres and TNA levels of the vaccinees are 
highly variable.  
  












1 263 561 66 
2 261 139 38 
3 784 734 493 
4 724 128 166 
5A 0 0 0 
6 533 470 318 
7 306 118 91 
8 538 149 89 
9 706 429 75 
10A 0 0 0 
            ASamples from control volunteers 
Table 11 – Average anti-PA and anti-LF antibody titres, and TNA levels in blood sera of 
AVP vaccinees.  Measurement of antibody levels was performed with at least four replicates; 













Figure 21 – Anti-PA antibody, Anti-LF antibody and TNA Levels in blood sera of AVP 
vaccinees. Measurement of antibody levels was performed with at least four replicates; TNA 
levels were measured in duplicates. Data has been plotted with 95% confidence interval about 
the mean. Sample 5 and 10 are from control volunteers. 




An analysis of the vaccinee data in Tables 10 and 11 shows that there is no clear correlation 
between vaccinee immunisation history (whether the number and/or timing of vaccinations) 
and antibody titre (whether anti-PA and/or anti-LF antibody titre), nor between anti-PA and/or 
anti-LF antibody titre and TNA level (Figure 22). Although there is evidence that anti-PA 
antibodies and TNA levels have good correlation in human studies [135, 293, 294], strong 
correlation was not observed in this study, potentially due to the small sample size. Other 
studies have shown that antibody and TNA levels can be highly variable in AVA and AVP 
vaccinees [3, 160, 294]. It is likely that TNA levels are modulated by a range of other factors, 
such as age, gender, T cell and B cell memory, and genetic differences (including HLA allelic 
differences) in humans could be responsible for variable antibody levels [14, 169, 295]. 
Previous research had investigated the impact of HLA polymorphisms on anti-PA antibody 
response in AVA vaccinees and found that DRB1–DQA1–DQB1 haplotypes *1501–*0102–
*0602, *0101–*0101–*0501 and *0102–*0101–*0501 were associated with significantly lower 
anti-PA antibody levels [163, 164]. However, it was not possible to identify such a correlation 
in this study.  
 
Nevertheless, it is apparent that, whereas most vaccinees have higher anti-PA antibody titres 
than anti-LF titres, none of the vaccinees have low levels of anti-LF antibodies. Moreover, the 
TNA levels do not suggest that any vaccinees have negligible capacity to neutralise the 
anthrax toxin, although, in the absence of vaccinated humans becoming infected with B. 
anthracis, it is unclear what TNA levels are necessary to afford protection. 
 
Given the current lack of knowledge about the TNA levels needed to provide protection against 
B. anthracis in humans, Anthrax vaccine studies have inevitable limitations, which are 
compounded here by the small-scale nature of the in vitro component of this study. 
Nevertheless, there are several important and novel conclusions. 






Figure 22 - Correlation between PA, LF and PA+LF antibody titres and TNA levels  in 
blood sera of AVP vaccines was 0.482, 0.548 and 0.639 respectively. Measurement of 
antibody levels was performed with at least four replicates; TNA levels were measured in 
duplicates. 
 
Although direct comparison of this study with other AVA studies is not possible, notably 
because of the different cell lines and different reference standard used for the TNA assay, it 
is interesting to contrast the results here with the large AVA study conducted by James and 
co-workers [25]. In that study, 69% of vaccinees had no detectable anti-LF antibodies, 
whereas all vaccinees in our study had moderate to high LF titres. Additionally, over 40% of 
the AVA vaccinees were deemed to have low toxin neutralisation activity; although it is hard 
to calibrate the TNA levels in our study, we do not see evidence of very low TNA activity, with 
only a single individual having a TNA (NF50)*1000 below 50. Taken together, these 
observations suggest that anti-LF antibody response from AVP potentially enhances 
protection, and are broadly consistent with previous observations about the efficacy of anti-LF 



































about the speed and extent of the anti-LF antibody response in comparison to the anti-PA 
response in naturally-acquired cutaneous Anthrax patients [169].    
 
5.4.3 Cytokine response 
 
5.4.3.1 IFNγ response 
 
PBMCs were found to be healthy when observed under the microscope. The cells were 
successfully stimulated with IMA/Ionomycin positive control, as expected. The average IFNγ 
response (pg/mL) was measured from PBMCs stimulated with rPA and rLF (Table 12, Figure 
23). IFNγ response was measured in two biological replicates, read in duplicate. 
 
Only AVP vaccinee sample 3 PBMCs showed a measurable IFNγ response when stimulated 
with rPA. Contrastingly, AVP vaccinee PBMCs samples 1, 3, 8 and 9 (50% of the sample set) 
showed a measurable IFNγ response when stimulated with rLF (Table 12, Figure 23).  
  







1 0 477 
2 0 0 
3 130 623 
4 0 0 
5 0 0 
6 0 0 
7 0 0 
8 0 91 
9 0 398 
10 0 661 
 




Figure 23 - IFNγ response in AVP vaccinees stimulated with rPA and rLF, only significant 
IFNγ response differences between non-treated and treated (p<0.05) have been reported with 
95% confidence interval. 





Again, the IFNy levels were variable in AVP vaccinees. There are a number of factors that one 
might attribute such variation to, including: differences in the epitopes being presented by 
MHC molecules, and/or the impact of HLA haplotypes (i.e. different epitopes presented by 
different MHC molecules with a single individual); cytokine or cytokine receptor gene 
polymorphisms; differences in cell surface molecules, vaccination history, age, sex and/or 
environmental factors [160, 162, 163].  
 
Control sample 5 PBMCs did not show IFNy response when stimulated with rPA or rLF, as 
expected.  Control sample 10 PBMCs showed a measurable IFNy when stimulated with rLF 
(Figure 23). This was most certainly a non-specific response to rLF, as the anti-LF antibody 
titres was below the detection limit (Table 11). The sample did not show IFNy response when 
stimulated with rPA. Ideally, the analysis should have been repeated, but due to lack of 
sample, this was not possible. 
 
This data suggests that there is a longer-lasting T cell response to rLF than rPA in AVP 
vaccinees. Generally, AVP vaccinees who had their primary vaccination some years ago 
(Samples 2, 4 and 7 – immunisation in 2012, 1999 and 2007 respectively), did not show IFNγ 
response when stimulated with rPA or rLF. Only AVP vaccinee 6 had their primary vaccination 
in 2015, yet there was no IFNγ response from rPA or rLF.  
 
Some attempts have been made to investigate the effect of HLA genotypes and haplotypes 
on cellular responses to PA. Ovsyannikova et al., [295] have shown that AVA vaccinees with 
HLA-DQA1 and HLA-DQB1 homozygosity showed significantly decreased PA-specific 
lymphocyte proliferation in comparison to heterozygous individuals. Sample 6 PBMCs, from 
an individual who is homozygous at both HLA-DRB1 and HLA-DQB1 loci (Table 10), did not 
exhibit an IFNy response to rPA or rLF, even though they had their primary immunisation 
recently (primary immunisation in 2015, booster in 2016). The individual’s homozygosity at 




both loci could explain the decreased cytokine response to rPA and rLF. Similarly, sample 2 
PBMCs, from an individual who is homozygous at the HLA-DPB1 locus, did not exhibit an 
IFNy response to rPA and rLF. This individual was immunised in 2012 and had regular 
boosters every 2 years. However, due to the small sample size, it is not possible to make 
robust conclusion regarding the relationship between IFNy response and HLA homozygosity 
in AVP vaccinees.  
 
The correlation between IFNy and anti-LF antibody titres (0.73) was considerably higher than 
that between IFNy and anti-PA antibody titres (0.21) (Figure 24). This data supports the 
hypothesis that LF has a T cell response that correlates with anti-LF antibody levels in AVP 
vaccinees. Previously, Ingram et al., [169] had reported that a strong CD4+ T cell response 
was observed in AVP vaccinees to LF only, whilst a T cell response to both PA and LF was 
observed in naturally-infected cutaneous Anthrax patients. Previous studies have concluded 
that PA-based humoral immunity may not be long lasting and that boosters may be essential 
[145, 293, 296-298]. This may be because of the shorter-lived memory T cell response from 
PA, as suggested by the results presented here.  
 
  






Figure 24 – Correlation between IFNy and Antibody levels. Only the significant IFNγ 
response differences between non-treated and treated (p<0.05) have been included in this 
comparison. IFNy cytokine response from control sample 10 was excluded from analysis.   
 
There was no measurable IFNy response from PA peptides (PA253-289, PA633-669, PA397-422, 
PA501-526, PA709-734) or LF peptides (LF570-595, LF650-675, LF672-697, LF710-735) in any of the samples. 
There are a number of possible explanations for this. It is possible that the assay was not 
optimised for IFNy response to rPA and rLF peptides. The availability of PBMCs from AVP 
vaccinees was the limiting factor, which meant that the optimisation work on the assay was 
also limited. Another possibility is that these epitopes are not immunodominant in these 
vaccinees. Further work would be required to investigate the underlying causes; however, this 
is beyond the scope of the current project.  
 
5.4.3.2 IL10 cytokine response  
 
There was no measurable IL10 response from rPA, rLF, PA peptides (PA253-289, PA633-669, 
























samples. This data confirmed that there is no IL10 response from rPA or rLF proteins in AVP 
vaccinees. 
 
5.4.4 Limitations of this study  
 
The major limitation of this study was that it was small, reflecting its proof-of-concept status. 
Consequently, it has been not been possible to draw firm conclusions regarding the effect of 
allelic differences in AVP vaccinees. In order to fully characterise the T cell response and 
contribution towards generation of protective antibodies, it would be necessary to conduct a 
large, ethnically diverse study (e.g. n=1000) with significant numbers of individuals of the same 
gender, and of similar age and vaccination history, etc.  
 
In this study, another major problem was that the ELISA assay for measuring cytokines 
needed to be developed and optimised on study samples (PBMCs having memory response 
to AVP proteins is not available off the shelf). However, there were insufficient samples to 
conduct both these preliminary experiments and to repeat the sample analysis. In future, these 




Anti-PA and anti-LF antibody data suggest that LF is an important component of AVP. Most 
vaccinees had high anti-PA antibody titres, but equally none of the vaccinees had low anti-LF 
antibodies levels. Although, it was not possible to differentiate the individual contribution of PA 
and LF towards TNA levels in AVP vaccinees, the presence of LF in AVP potentially enhances 
overall protection from AVP. Further, T cell study data supports the hypothesis that LF has a 
stronger T cell response than PA in AVP vaccinees. This is broadly consistent with data 
reported by Ingram et al., [169] in AVP vaccinees and naturally infected cutaneous Anthrax 
patients.   






6.1 Project Summary 
 
LC-MS/MS studies found that AVP is a complex mixture of at least 138 B. anthracis proteins, 
including PA (65%), LF (8%) and EF (3%), using DIA based Hi3 label free quantitation. 
NetMHCIIpan predicted that peptides from all eight abundant proteins are likely to be 
presented to T cells, a pre-requisite for protection; however, the number of such peptides 
varied considerably for different HLA alleles. This work demonstrates that AVP contains many 
protein components that have not previously been identified and suggests that several 
proteins not normally considered relevant – notably LF, EF, PX01 and Chaperonin – are 
reasonably abundant within AVP and have the potential to afford protection for individuals with 
HLA allele combinations that are predicted to have relatively few PA epitopes.  
 
These analyses highlighted two important properties of the AVP vaccine that have not been 
previously established. Firstly, the effectiveness of AVP within humans does not depend on 
PA alone; there is compelling evidence to suggest that LF has a protective role, with 
computational predictions suggesting that additional proteins may be important for individuals 
with specific HLA allele combinations. Secondly, in spite of differences in the sequences of 
key antigenic proteins from different B. anthracis strains, computational analysis suggested 
that these do not affect the protection that AVP affords to strains other than the vaccine’s 
source strain. Nevertheless, there remains a small possibility that an individual’s 
immunodominant vaccine response, induced by the Sterne strain, may be comparatively 
ineffective against a different strain if one or more critical epitopes are absent or different in 
that strain.  
 
  




6.2 Future Directions 
 
This work has demonstrated that AVP is composed of at least 138 proteins and computational 
studies have shown that many of these proteins are potentially important in inducing an 
immune response against Anthrax. Further work is needed to validate this data experimentally 
using in vitro MHC molecules and antigen-binding studies - by measuring binding affinity of 
antigen epitopes to MHC molecules using bio-layer interferometry technology or competitive 
ELISAs. Additionally, it would be beneficial to identify the frequency of cytokine-producing cells 
and visualise the T-cell response to a specific antigen using the intracellular cytokine staining 
method on a flow cytometer. It could also be combined with staining for phenotypic markers 
for identifying cell types (e.g. effector or memory T cell).   
 
Intracellular cytokine staining (ICS) is a popular method for visualizing cellular responses, 
most often T-cell responses to antigenic or mitogenic stimulation. It can be coupled with 
staining for other functional markers, such as upregulation of CD107 or CD154, as well as 
phenotypic markers that define specific cellular subsets, e.g. effector and memory T-cell 
compartments. 
  
Further, future studies should incorporate many more vaccinees and will need to explicitly 
evaluate the potential importance of HLA and protein specificity highlighted by the 
computational results. Further, AVP is known to have side effects (e.g. local reactions, fever 
and influenza-like symptoms). In future, it would be useful to identify proteins responsible for 
side effects and remove them from AVP to develop a next generation vaccine. 
 
This work also shows the potential importance of considering inter-strain differences and 
identifies specific epitopes that are modified or absent in a subset of other B. anthracis strains. 
Further work is needed to identify whether these epitopes are important targets of the 
protective T cell response induced by the vaccine in some individuals.  
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Appendix 1 – Python Script to enable automated prediction of MHC class II peptides 
 
#!/usr/bin/env python 







from datetime import datetime 
 
#Splits allele list into evenly sized chunks of 20 
def split_alleles(list): 
    for i in range(0, len(list), 20): 
        yield list[i:i + 20] 
 
#Sets data for POST submission 
post_data = { 
 "configfile" : (None, "/usr/opt/www/pub/CBS/services/NetMHCIIpan-3.2/NetMHCIIpan-
3.2.cf"), 
 "inp" : (None, "0"), 
 "SEQSUB" : (None, ""), 
 "length" : (None, "15"), 
 "PEPPASTE" : (None, ""), 
 "PEPSUB" : (None, ""), 




 "master" : (None, "1"), 
 "slave0" : (None, "DRB1_0104"), 
 "MHCSEQPASTEa" : (None, ""), 
 "MHCSEQSUBa" : (None, ""), 
 "MHCSEQPASTEb" : (None, ""), 
 "MHCSEQSUBb" : (None, ""), 
 "thrs" : (None, "2"), 
 "thrw" : (None, "10"), 
 "thrf" : (None, "10"), 
 "sort" : (None, "on"), 
 "histhr" : (None, "10") 
} 
 
#Lists all HLA alleles for MHCII 
#REPLACE THIS WITH LIST OF YOUR ALLELES 
alleles = ["HLA-DPA10201-DPB10101", "HLA-DPA10103-DPB10201", "HLA-DPA10103-
DPB10401", "HLA-DPA10301-DPB10402", "HLA-DPA10201-DPB10501", "HLA-DQA10501-
DQB10201", "HLA-DQA10501-DQB10301", "HLA-DQA10301-DQB10302", "HLA-
DQA10401-DQB10402", "HLA-DQA10101-DQB10501", "HLA-DQA10102-DQB10602", 
"DRB1_0101", "DRB1_0301", "DRB1_0401", "DRB1_0404", "DRB1_0405", "DRB1_0701", 
"DRB1_0802", "DRB1_0901", "DRB1_1101", "DRB1_1302", "DRB1_1501", "DRB3_0101", 
"DRB4_0101", "DRB5_0101", "H-2-IAb"] 
 
#Opens all FASTA files in given directory 
#REPLACE THIS WITH THE LOCATION OF YOUR FILES 
FASTA_directory = "C:\Tapasvi\PhD\BioInformatics Stuff\Protective antigen\Fasta 
files\python" 
FASTA_files = os.listdir(FASTA_directory) 





i = 1 
i_max = len(FASTA_files) 
 
#For each FASTA in directory 
for _FASTA_file in FASTA_files: 
  
 #Prints progress 
 print("File %s of %s: %s" % (i, i_max, _FASTA_file)) 
  
 #Sets empty lists for results 
 allele_50_results = [] 
 allele_500_results = [] 
  
 #Extract sequence from FASTA file 
 with open(FASTA_directory + "\\" + _FASTA_file, "r") as _file: 
  _file_contents = _file.read() 
 _file.close() 
 _protein_seq = "".join(_file_contents.strip().split("\n")[1:]) 
  
 #Set session 
 session = requests.session() 
 
 #Adds sequence and allele 
 post_data["SEQPASTE"] =  (None, _protein_seq) 
  
 #Uploads results in chunks of 20 alleles 
 for allele_list in split_alleles(alleles): 





  #Uploads alleles in packets of 20 (maximum allowed by server) 
  post_data["allele"] = (None, ",".join(allele_list)) 
   
  #Makes POST request to server 
  response = session.post("http://www.cbs.dtu.dk/cgi-bin/webface2.fcgi", 
files=post_data) 
   
  #Processes initial response to fetch job ID 
  job_ID = re.findall(r"\!\-\- jobid\: (.+?) status", response.text, re.DOTALL)[0] 
  print("\tJob ID: %s" % job_ID) 
   
  #Waits and checks job progress every 5 seconds 
  _processing = True 
  response = "" 
  u_i = 1 
  while _processing: 
   response = session.get("http://www.cbs.dtu.dk/cgi-
bin/webface2.fcgi?jobid=%s" % job_ID) 
   if "Number of strong binders" in response.text: 
    break 
   print("\t\tWaiting for results ... %s" % u_i) 
   u_i += 1 
   time.sleep[85] 
   
  #Gets results from response table and adds to appropriate list 
  result_tables = re.findall(r"Allele\:.+?\-[85].+?\-[85](.+?)\-[85]", response.text, 
re.DOTALL) 




  for result_table in result_tables: 
   new_50_table = [] 
   new_500_table = [] 
    
   for row in result_table.strip().split("\n"): 
    row_cells = re.split(r"\s{2,}If", row.strip()) 
     
    if float(row_cells[8]) <= 50: 
     new_50_table.append(",".join(row_cells)) 
      
    if float(row_cells[8]) <= 500: 
     new_500_table.append(",".join(row_cells)) 
   
   allele_50_results += new_50_table 
   allele_500_results += new_500_table 
  
 #Saves all alleles with <50nM affinity to own file 
 with open("%s-50nM Results.csv" % _FASTA_file.split(".")[0], "w") as _file: 
  _file.write("Seq,Allele,Peptide,Identity,Pos,Core,Core_Rel,1-
log50k(aff),Affinity(nM),%Rank,Exp_Bind,BindingLevel\n" + "\n".join(allele_50_results)) 
 _file.close() 
  
 #Saves all alleles with <500nM affinity to own file 
 with open("%s-500nM Results.csv" % _FASTA_file.split(".")[0], "w") as _file: 
  _file.write("Seq,Allele,Peptide,Identity,Pos,Core,Core_Rel,1-
log50k(aff),Affinity(nM),%Rank,Exp_Bind,BindingLevel\n" + "\n".join(allele_500_results)) 
 _file.close() 
 










Appendix 2 – Python Script to enable automated prediction of MHC class I peptides 
 
#!/usr/bin/env python 







from datetime import datetime 
 
#Splits allele list into evenly sized chunks of 20 
def split_alleles(list): 
    for i in range(0, len(list), 20): 
     yield list[i:i + 20] 
 
#Sets data for POST submission 
post_data = { 
 "configfile" : (None, "/usr/opt/www/pub/CBS/services/NetMHCpan-
3.0/NetMHCpan.cf"), 
 "inp" : (None, "0"), 
 "SEQSUB" : (None, ""), 
 "length" : (None, "9"), 
 "PEPPASTE" : (None, ""), 
 "PEPSUB" : (None, ""), 
 "master" : (None, "1"), 
 "slave0" : (None, "HLA-A01:01"), 




 "MHCSEQPASTEa" : (None, ""), 
 "MHCSEQSUBa" : (None, ""), 
 "MHCSEQPASTEb" : (None, ""), 
 "MHCSEQSUBb" : (None, ""), 
 "thrs" : (None, "2"), 
 "thrw" : (None, "10"), 
 "thrf" : (None, "10"), 
 "sort" : (None, "on"), 
 "histhr" : (None, "10") 
} 
 
#Lists all HLA alleles for MHCI 
#REPLACE THIS WITH LIST OF YOUR ALLELES 
alleles = ["HLA-A02:01", "HLA-A11:01", "HLA-A01:01", "HLA-A03:01", "HLA-A31:01", "HLA-
A33:03", "HLA-A02:06", "HLA-A26:01", "HLA-A30:01", "HLA-B35:01", "HLA-B51:01", "HLA-
B40:01", "HLA-B44:03", "HLA-B07:02", "HLA-B15:01", "HLA-B08:01", "HLA-B58:01", "HLA-
B27:05", "HLA-B39:05", "HLA-C07:02", "HLA-C04:01", "HLA-C03:04", "HLA-C01:02", "HLA-
C07:01", "HLA-C06:02", "HLA-C03:03", "HLA-C08:01", "HLA-C15:02", "HLA-C12:02"] 
 
#Opens all FASTA files in given directory 
#REPLACE THIS WITH THE LOCATION OF YOUR FILES 
FASTA_directory = "C:\Tapasvi_11Sep19\PhD\BioInformatics Stuff\Protective antigen\Fasta 
files\python" 
FASTA_files = os.listdir(FASTA_directory) 
 
i = 1 
i_max = len(FASTA_files) 
 




#For each FASTA in directory 
for _FASTA_file in FASTA_files: 
 
 #Prints progress 
 print("File %s of %s: %s" % (i, i_max, _FASTA_file)) 
 
 #Sets empty lists for results 
 allele_SB_results = [] 
 allele_WB_results = [] 
 
 #Extract sequence from FASTA file 
 with open(FASTA_directory + "\\" + _FASTA_file, "r") as _file: 
  _file_contents = _file.read() 
 _file.close() 
 _protein_seq = "".join(_file_contents.strip().split("\n")[1:]) 
 
 #Set session 
 session = requests.session() 
 
 #Adds sequence and allele 
 post_data["SEQPASTE"] =  (None, _protein_seq) 
 
 #Uploads results in chunks of 20 alleles 
 for allele_list in split_alleles(alleles): 
 
  #Uploads alleles in packets of 20 (maximum allowed by server) 
  post_data["allele"] = (None, ",".join(allele_list)) 
 




  #Makes POST request to server 
  response = session.post("http://www.cbs.dtu.dk/cgi-bin/webface2.fcgi", 
files=post_data) 
 
  #Processes initial response to fetch job ID 
  job_ID = re.findall(r"\!\-\- jobid\: (.+?) status", response.text, re.DOTALL)[0] 
  print("\tJob ID: %s" % job_ID) 
 
  #Waits and checks job progress every 5 seconds 
  _processing = True 
  response = "" 
  u_i = 1 
  while _processing: 
   response = session.get("http://www.cbs.dtu.dk/cgi-
bin/webface2.fcgi?jobid=%s" % job_ID) 
   if "Number of strong binders" in response.text: 
    break 
   print("\t\tWaiting for results ... %s" % u_i) 
   u_i += 1 
   time.sleep[85] 
 
  #Gets results from response table and adds to appropriate list 
  result_tables = re.findall(r"Allele\:.+?\-[85].+?\-[85](.+?)\-[85]", response.text, 
re.DOTALL) 
  for result_table in result_tables: 
   new_SB_table = [] 
   new_WB_table = [] 
 




   for row in result_table.strip().split("\n"): 
    row_cells = re.split(r"\s{2,}", row.strip()) 
 
    if "sb" in row_cells[-1].lower(): 
     new_SB_table.append(",".join(row_cells)) 
           
    if "wb" in row_cells[-1].lower(): 
     new_WB_table.append(",".join(row_cells)) 
 
   allele_SB_results += new_SB_table 
   allele_WB_results += new_WB_table 
 
 #Saves all alleles with <50nM affinity to own file 
 with open("%s-SB Results.csv" % _FASTA_file.split(".")[0], "w") as _file: 





 #Saves all alleles with <500nM affinity to own file 
 with open("%s-WB Results.csv" % _FASTA_file.split(".")[0], "w") as _file: 











Appendix 3 – B. anthracis Strain Collection 
 
Strain Name Genbank No. Source 
Ames A0462 CP010793.1 American Type Culture Collection 
Ames BA1004 CP009980.1 USAMRIID 
A0248 CP001599.1 No information 
A1144 CP010853.1 
Argentinian isolate with mucoid colony 
morphology 
A16R CP001975.1 analysed in China, souce unknown 
A16 CP001971.1 analysed in China, souce unknown 
A2012 AE011190.1 Florida isolate 
BA0052 CP007703 USARMIID 
BA1015 CP009543.1 USAMRIID 
BA1035 CP009699.1 USAMRIID 
BFV CP007703.1 USAMRIID 
Canadian Bison CP010321.1 USAMRIID 
CDC 684 CP001216.1 Los Alamos National Laboratory 
Delta Sterne CP008752 USARMIID 
HYU01 CP008847.1 Soil Samples in the Korean Peninsula 
H9401 CP002092.1 isolate from korean patient 
Isolate IT Carb 1-6241 AJ413937.1 
B. anthracis ‘Carbosap’ vaccine strain, 
used as vaccine in Italy 
Isolate IT Carb3-6254 AJ413936.1 
B. anthracis ‘Carbosap’ vaccine strain, 
used as vaccine in Italy 
K3 CP009331.1 USAMRIID 





human cutaneous Anthrax stain in 
Greece 
Ohio CP009340.1 USAMRIID 
PAK-1 CP009324.1 USAMRIID 
Pasteur CP009476.1 USAMRIID 
Pasteur-like JNOD01000001 USARMIID 
Pollino NZ_CP010813.1 Cattle Italy 
P.NO2 KT186230.1 
analysed in China, px01 from attenuated 
pasteur vaccine strains 





Shikan-NIID AP014834.1 horses Tokyo Japan 
SK-102 CP009463.1 USAMRIID 
Stendel CP014177.1 cattle in germany 
Sterne CP009540.1 USAMRIID 
Sterne NG CP035988.1 N/A 
SVA11 NZ_CP006742.1 National Veterinary Institute in Sweden 
Turkey32 CP009316.1 USAMRIID 
VCM1168 KP213102.1 northern Vietnam 
V770-NP-1R CP009597.1 USAMRIID 
Vollum 1B CP009327.1 USAMRIID 





1C3 KP213104 northern Vietnam 
4NS KP213103.1 northern Vietnam 











horses Tokyo Japan 
34F2 JQ798178.1 recombinant PA 
2002013094 CP009902.1 USAMRIID 
2000031021 CP007617 USARMIID 
 
  




Appendix 4 – Proteins identified in CF using LC-MS/MS analysis  
 
Uniprot Accession No. B. Anthracis Protein Name 
P13423 Protective antigen 
P15917 Lethal factor  
P40136 Calmodulin-sensitive adenylate cyclase 
Q81X78 Enolase 
Q9X360 PXO1-90  
Q81VE1 60 kDa chaperonin  
Q81QZ5 Alcohol dehydrogenase  
Q81X75 Phosphoglycerate kinase  
Q81K80 L-lactate dehydrogenase 2  
Q81KZ1 Pyruvate kinase  
P02769 Unknown Entry 
Q81K75 Glucose-6-phosphate isomerase  
Q81M66 Leucine dehydrogenase  
Q81YX1 Formate acetyltransferase  
Q81VT3 Elongation factor G  
Q81X76 Triosephosphate isomerase  
Q81VE0 GMP synthase [glutamine-hydrolyzing]  
Q81P59 Chorismate mutase  
P94217 S-layer protein EA1  
Q81M07 Probable glycine dehydrogenase (decarboxylating) subunit 1  
Q81Y15 Transketolase  
Q81ZG8 Bifunctional purine biosynthesis protein PurH  
Q81XT6 Glutamine synthetase  




Q81M06 Aminomethyltransferase  
Q81LL7 Aldehyde-alcohol dehydrogenase  
Q81X77 2_3-bisphosphoglycerate-independent phosphoglycerate mutase  
Q81KZ0 ATP-dependent 6-phosphofructokinase  
TRYP_PIG Entry Unknown Entry 
Q81W29 Inosine-5'-monophosphate dehydrogenase  
Q81ZF8 1-pyrroline-5-carboxylate dehydrogenase  
Q81W27 Pyridoxal 5'-phosphate synthase subunit PdxS  
Q81Y22 N-acetylmuramoyl-L-alanine amidase  
Q81ZC4 Alkyl hydroperoxide reductase  
Q81WM8 Polyribonucleotide nucleotidyltransferase  
Q81RT5 Peptidase P60  
Q81VV3 Glutamate--tRNA ligase  
Q81JY4 Serine hydroxymethyltransferase  
Q81ZH6 Adenylosuccinate lyase  
Q81UH4 Amidase  
Q81SA0 Fumarate hydratase class II  
Q81VN5 Glutamine--fructose-6-phosphate aminotransferase [isomerizing]  
Q81Z72 Chemical-damaging agent resistance protein C  
Q81UL6 Glyceraldehyde-3-phosphate dehydrogenase  
Q81RQ4 3-dehydroshikimate dehydratase  
Q81KW3 Alanine dehydrogenase  
Q81VU0 50S ribosomal protein L7/L12  
Q81Y95 Serine protease  
Q81JI9 Adenylosuccinate synthetase  
Q81MR3 
Dihydrolipoamide acetyltransferase component of pyruvate 
dehydrogenase complex  




Q81ZH1 Amidophosphoribosyltransferase  
Q81LS1 Protein GrpE  
Q81VN7 Phosphoglucosamine mutase  
Q81WN5 Aspartate-semialdehyde dehydrogenase  
Q81UA1 Putative S-layer protein  
Q81L19 Peptidase M28  
Q81SV8 Nucleoside diphosphate kinase  
Q81L45 Cell surface protein  
Q81QP8 Isochorismatase  
Q81KQ7 Aminopeptidase  
Q6HSF4 Malate dehydrogenase  
Q81KP6 Peptidase_ M42 family  
Q81YG1 Putative lipoprotein  
D1MPY3 Putative malate dehydrogenase  
Q81LL9 High-affinity heme uptake system protein isdE  
Q81XS0 Ferredoxin--NADP reductase 2  
Q81KU8 Probable thiol peroxidase  
Q81RE1 Formate--tetrahydrofolate ligase  
Q81VX2 Cysteine synthase  
Q81X74 Glyceraldehyde-3-phosphate dehydrogenase  
Q81JT1 Agmatinase  
Q81V80 Putative pyridoxal phosphate-dependent acyltransferase  
Q81ZH8 N5-carboxyaminoimidazole ribonucleotide mutase  
Q81WK9 Elongation factor Ts  
Q81TL8 Tryptophan synthase beta chain  
Q81M65 Phosphate butyryltransferase  
Q81RW4 L-lactate dehydrogenase 1  




Q81UU2 Nitroreductase  
Q81M84 Peptidase_ M20/M25/M40 family  
Q81XP7 NifU domain protein  
Q81TL7 Tryptophan synthase alpha chain  
Q81LG0 Nicotinate-nucleotide diphosphorylase (Carboxylating)  
Q81JR4 Phosphate acetyltransferase  
Q81V19 Cell wall-binding protein  
Q81VE2 10 kDa chaperonin  
Q81TX2 Putative S-layer protein  
Q81VA6 Alanine dehydrogenase  
Q81XS5 Probable cytosol aminopeptidase  
Q81L73 Thioredoxin  
Q81NS6 Signal peptidase I  
Q81RP6 Peptidase  
Q81JF9 3-oxoacyl-[acyl-carrier-protein] synthase 2  
Q81VZ2 Putative septation protein SpoVG 
Q81L44 Cell surface protein 
Q81X16 UDP-N-acetylglucosamine 2-epimerase 
Q81SX5 30S ribosomal protein S1 
Q81K96 1_4-dihydroxy-2-naphthoyl-CoA synthase 
Q81JW4 Fructose-bisphosphate aldolase 
Q81ZG7 Phosphoribosylamine--glycine ligase  
Q81JI2 30S ribosomal protein S6  
Q81JY0 PTS system glucose-specific EIIA component  
Q81V33 Probable transaldolase 1  
Q81WW9 Conserved domain protein 
Q81JT0 Polyamine aminopropyltransferase 1  




Q81Z71 Chemical-damaging agent resistance protein C  
Q81U41 HIT family protein  
Q81MG5 Peptidyl-prolyl cis-trans isomerase  
Q81MB5 6_7-dimethyl-8-ribityllumazine synthase  
Q81KX5 Metallopeptidase  
Q81MH4 N-acetylglucosamine-6-phosphate deacetylase  
Q81KU3 3-demethylubiquinone-9 3-methyltransferase  
Q81UU2 Nitroreductase  
Q81L43 Heme uptake protein IsdC  
Q81SW2 GTP cyclohydrolase 1  
Q81T83 Thioredoxin  
Q81VP8 30S ribosomal protein S9  
Q81UR6 Uncharacterized protein  
Q81LD0 Glutamate-1-semialdehyde 2_1-aminomutase 2  
Q81VW3 Lysine--tRNA ligase  
Q81PX6 Uncharacterized protein  
Q81MR2 2-oxoisovalerate dehydrogenase  
Q81U22 Ferrochelatase 1  
Q81WK7 GTP-sensing transcriptional pleiotropic repressor CodY  
Q81TB9 Abortive phage infection protein  
Q81T55 D-isomer specific 2-hydroxyacid dehydrogenase family protein  
Q81WQ9 2-oxoacid ferredoxin oxidoreductase  
Q81QQ0 Isochorismate synthase  
Q81K32 UDP-N-acetylglucosamine 2-epimerase  
Q81WN7 4-hydroxy-tetrahydrodipicolinate synthase  
Q81R67 ESAT-6-like protein  
Q81MR4 Dihydrolipoyl dehydrogenase  




Q81VU3 50S ribosomal protein L11  
Q81JR3 Putative heme-dependent peroxidase BA_5637  
Q81XJ7 L-lactate dehydrogenase 3  
Q81W25 Serine--tRNA ligase  
Q81LK9 Transcription elongation factor GreA  
Q81L16 50S ribosomal protein L35  
Q81WY2 Lipoteichoic acid synthase-like yqgS  
Q6I4E9 tRNA N6-adenosine threonylcarbamoyltransferase  
Q81UR3 Efflux transporter periplasmic adaptor subunit  
Q81P32 Antibiotic biosynthesis monooxygenase  
Q81KI0 S-adenosylmethionine synthase  
Q81JI3 Single-stranded DNA-binding protein  
Q81X56 Thioredoxin reductase  
Q81SU0 4-hydroxy-tetrahydrodipicolinate reductase  
Q81V38 Ribokinase  
Q81SP8 Uncharacterized protein  
Q81UR3 Efflux transporter periplasmic adaptor subunit 
Q81R29 Cell division protein FtsK 
Q81JI3 Single-stranded DNA-binding protein 
Q81VP0 Arginase 
B9ZW32 Hypoxanthine phosphoribosyltransferase 
Q81VV4 2-C-methyl-D-erythritol 2_4-cyclodiphosphate synthase 
Q81SB6 Uncharacterized protein 
Q81ZF6 Isochorismatase 
Q81JX8 Uncharacterized protein ywrF 
Q81LJ1 HTH-type transcriptional regulator CymR 
Q81PA3 Sporulation protein 




Q81XF6 DNA methyltransferase  
Q81L16 50S ribosomal protein L35  
Q81K32 UDP-N-acetylglucosamine 2-epimerase  
Q81YR9 Ankyrin repeat domain protein  
Q81QQ0 Isochorismate synthase  
Q81JI3 Single-stranded DNA-binding protein  
Q81SP6 Uncharacterized protein  
Q81T89 Transcriptional regulator_ Bla/Mec family  
Q81JR3 Putative heme-dependent peroxidase BA_5637  
Q81U47 Uncharacterized protein  
Q81WT0 Probable N-acetyl-alpha-D-glucosaminyl L-malate deacetylase 2  
Q81VW7 7_8-dihydroneopterin aldolase  
Q81VR5 50S ribosomal protein L6  
Q81SX3 Uncharacterized protein  
Q6I4E9 tRNA N6-adenosine threonylcarbamoyltransferase  
Q81YT0 Internalin  
Q81LL6 Cys/Met metabolism PLP-dependent enzyme  
Q81LW0 Superoxide dismutase [Mn] 1  
Q81L16 50S ribosomal protein L35  
Q81UH0 Ornithine cyclodeaminase  
Q81WQ6 Stage V sporulation protein S  
Q81R02 Putative lipoprotein  
Q81JW2 Uncharacterized protein  
Q81VT2 Elongation factor Tu  
Q81MR1 Pyruvate dehydrogenase  
Q81XN4 Putative lipoprotein  
Q81KN9 RNA 2'_3'-cyclic phosphodiesterase 




Appendix 5 – Proteins identified in AVP using LC-MS/MS analysis 
 
Uniprot Accession No. Protein Description 
P13423 Protective antigen 
P15917 Lethal factor 
P40136 Calmodulin-sensitive adenylate cyclase 
Q81X78 Enolase 
Q9X360 PXO1-90 
Q81QZ5 Alcohol dehydrogenase 
Q81VE1 60 kDa chaperonin 
Q81KZ1 Pyruvate kinase 
Q81K80 L-lactate dehydrogenase 2 
Q81VT3 Elongation factor G 
Q81YX1 Formate acetyltransferase 
P02769 Unknown Entry 
Q81M66 Leucine dehydrogenase 
Q81X75 Phosphoglycerate kinase 
Q81K75 Glucose-6-phosphate isomerase 
Q81VE0 GMP synthase [glutamine-hydrolyzing] 
P94217 S-layer protein EA1 
Q81ZF8 1-pyrroline-5-carboxylate dehydrogenase 
TRYP_PIG Entry Unknown Entry 
Q81XT6 Glutamine synthetase 
Q81W29 Inosine-5'-monophosphate dehydrogenase 
Q81M08 Probable glycine dehydrogenase (decarboxylating) subunit 2 
Q81Y15 Transketolase 




Q81Y95 Serine protease 
Q81X77 2_3-bisphosphoglycerate-independent phosphoglycerate mutase 
Q81UH4 Amidase 
Q81JY4 Serine hydroxymethyltransferase 
Q81ZC4 Alkyl hydroperoxide reductase 
Q81M07 Probable glycine dehydrogenase (decarboxylating) subunit 1 
Q81V19 Cell wall-binding protein 
Q81L45 Cell surface protein 
Q81WM8 Polyribonucleotide nucleotidyltransferase 
Q81ZG8 Bifunctional purine biosynthesis protein PurH 
Q81M06 Aminomethyltransferase 
Q81X74 Glyceraldehyde-3-phosphate dehydrogenase 
Q81ZH6 Adenylosuccinate lyase 
Q81VN5 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 
Q81P59 Chorismate mutase 
Q81QQ0 Isochorismate synthase 
Q81SV8 Nucleoside diphosphate kinase 
D1MPY3 Putative malate dehydrogenase 
Q81UA1 Putative S-layer protein 
Q81VV3 Glutamate--tRNA ligase 
Q81Y22 N-acetylmuramoyl-L-alanine amidase 
Q81TX2 Putative S-layer protein 
Q81KZ0 ATP-dependent 6-phosphofructokinase 
Q81TL7 Tryptophan synthase alpha chain 
Q81JW4 Fructose-bisphosphate aldolase 
Q81W27 Pyridoxal 5'-phosphate synthase subunit PdxS 
Q81KW3 Alanine dehydrogenase 




Q81VN7 Phosphoglucosamine mutase 
Q81VU0 50S ribosomal protein L7/L12 
Q81LL7 Aldehyde-alcohol dehydrogenase 
Q81X76 Triosephosphate isomerase 
Q81JI9 Adenylosuccinate synthetase 
Q6HSF4 Malate dehydrogenase 
Q81LB8 Trigger factor 
Q81L43 Heme uptake protein IsdC 
Q81UR6 Uncharacterized protein 
Q81LL9 High-affinity heme uptake system protein isdE 
Q81TS4 Dipeptide-binding protein dppE 
Q81TL8 Tryptophan synthase beta chain 
Q81Z71 Chemical-damaging agent resistance protein C 
Q81LS1 Protein GrpE OS=Bacillus anthracis GN=grpE PE=3 SV=1 
Q81ZC5 Alkyl hydroperoxide reductase subunit F 
Q81LG0 Nicotinate-nucleotide diphosphorylase (Carboxylating) 
Q81Z72 Chemical-damaging agent resistance protein C 
Q81R29 Cell division protein FtsK 
Q81SA0 Fumarate hydratase class II 
Q81XS0 Ferredoxin--NADP reductase 2 
Q81RP6 Peptidase 
Q81UL6 Glyceraldehyde-3-phosphate dehydrogenase 
Q81SX5 30S ribosomal protein S1 
Q81LW0 Superoxide dismutase [Mn] 1 
Q81WN5 Aspartate-semialdehyde dehydrogenase 
Q81WK9 Elongation factor Ts 
Q81KP6 Peptidase_ M42 family 




Q81RQ4 3-dehydroshikimate dehydratase 
Q81K96 1_4-dihydroxy-2-naphthoyl-CoA synthase 
Q81MR4 Dihydrolipoyl dehydrogenase 
Q81QP8 Isochorismatase 
Q81VE2 10 kDa chaperonin 
Q81ZG7 Phosphoribosylamine--glycine ligase 
Q81RW4 L-lactate dehydrogenase 1 
Q81JT0 Polyamine aminopropyltransferase 1 
Q81XP7 NifU domain protein 
Q81L19 Peptidase M28 
Q81JT1 Agmatinase 
Q81VT2 Elongation factor Tu 
Q81ZH8 N5-carboxyaminoimidazole ribonucleotide mutase 
Q81RT5 Peptidase P60 
Q81NS6 Signal peptidase I 
Q81M65 Phosphate butyryltransferase 
Q81JI3 Single-stranded DNA-binding protein 
Q81LL6 Cys/Met metabolism PLP-dependent enzyme 
Q81KW2 Universal stress protein 
Q81VW3 Lysine--tRNA ligase 
Q81XJ7 L-lactate dehydrogenase 3 
Q81V33 Probable transaldolase 1 
Q81WY2 Lipoteichoic acid synthase-like yqgS 
Q81WW9 Conserved domain protein 
Q81JF9 3-oxoacyl-[acyl-carrier-protein] synthase 2 
Q81VX2 Cysteine synthase 
Q81T09 Purine nucleoside phosphorylase DeoD-type 




Q81MR2 2-oxoisovalerate dehydrogenase 
Q81MB5 6_7-dimethyl-8-ribityllumazine synthase 
Q81TX0 Isocitrate lyase 
Q81W04 Transition state regulator Abh 
Q81VA6 Alanine dehydrogenase 
Q81KQ7 Aminopeptidase 
Q81RR7 LytR family transcriptional regulator 
Q81V80 Putative pyridoxal phosphate-dependent acyltransferase 
Q81L44 Cell surface protein 
Q81ZG0 Putative lipoprotein 
Q81JI2 30S ribosomal protein S6 
Q81WL1 Ribosome-recycling factor 
Q81VZ2 Putative septation protein SpoVG 
Q81UU2 Nitroreductase 
Q81ZH1 Amidophosphoribosyltransferase 
Q81U83 UPF0145 protein BA_1001/GBAA_1001/BAS0936 
Q81SW3 DNA-binding protein 
Q81LS2 Chaperone protein DnaK 
Q81V16 LPXTG-site transpeptidase family protein 
Q81VU1 50S ribosomal protein L10 
Q81T55 D-isomer specific 2-hydroxyacid dehydrogenase family protein 
Q81L70 Enoyl-CoA hydratase 
Q81TN0 Putative phosphoesterase BA_1241/GBAA_1241/BAS1148 
Q81VQ4 DNA-directed RNA polymerase subunit alpha 
Q81LK9 Transcription elongation factor GreA 
Q81ZE6 Diacylglycerol kinase 
Q81TC3 Conserved domain protein 




Q81P32 Antibiotic biosynthesis monooxygenase 
Q81VS2 50S ribosomal protein L29 
Q81MG5 Peptidyl-prolyl cis-trans isomerase 
Q81X22 Endopeptidase lytF 
Q81X22 Endopeptidase lytF 
Q81MY9 Probable transaldolase 2 
Q81KI0 S-adenosylmethionine synthase 
Q81L32 Asparagine--tRNA ligase 
Q9X366 PXO1-97 
Q81VR5 50S ribosomal protein L6 
Q81L73 Thioredoxin 
Q81LB4 Uncharacterized protein 
Q81MP6 Uncharacterized protein 
Q81L70 Enoyl-CoA hydratase 
Q81VZ2 Putative septation protein SpoVG 
B9ZW32 Hypoxanthine phosphoribosyltransferase 
Q81L73 Thioredoxin 
Q81U83 UPF0145 protein BA_1001/GBAA_1001/BAS0936 
Q81WL1 Ribosome-recycling factor 
Q81W77 Transcriptional regulator 
Q81L70 Enoyl-CoA hydratase 
B9ZW32 Hypoxanthine phosphoribosyltransferase 
Q81VZ2 Putative septation protein SpoVG 
Q81R20 FMN-dependent NADH-azoreductase 3 
Q81L44 Cell surface protein 
P49051 S-layer protein sap 
Q81KI0 S-adenosylmethionine synthase 




Q81U83 UPF0145 protein BA_1001/GBAA_1001/BAS0936 
Q81WK7 GTP-sensing transcriptional pleiotropic repressor CodY 
Q81VZ2 Putative septation protein SpoVG 
Q81L70 Enoyl-CoA hydratase 
B9ZW32 Hypoxanthine phosphoribosyltransferase 
Q81ME6 Transcriptional regulator_ MarR family 
Q81L44 Cell surface protein 
Q81TB9 Abortive phage infection protein 
Q81VL4 Lipoprotein 
Q81TC1 Phosphoglycerate mutase 
Q81UN3 Acetyltransferase 
Q9X388 PXO1-131 
Q81JU4 Methionine aminopeptidase 
Q81M74 UPF0403 protein BA_4378/GBAA_4378/BAS4061 
Q81QA3 TetR family transcriptional regulator 
Q81XS7 Phosphoglucomutase 
Q81XK8 Glycine cleavage system H protein 
Q81Q77 Uncharacterized protein 
Q81T89 Transcriptional regulator_ Bla/Mec family 
Q81PW3 Spore cortex-lytic enzyme 
Q81LW2 Penicillin-binding protein 
Q81U72 3'-5' exoribonuclease YhaM 
Q81KU8 Probable thiol peroxidase 
Q81VT8 DNA-directed RNA polymerase subunit beta 
D1MPU6 Ribonucleoside-diphosphate reductase 
Q81VV9 ATP-dependent Clp protease ATP-binding subunit ClpC 
Q81JR3 Putative heme-dependent peroxidase BA_5637 





Q81ZH0 Phosphoribosylformylglycinamidine cyclo-ligase 
Q81V01 Quinol oxidase subunit 2 
Q81LC9 Delta-aminolevulinic acid dehydratase 
Q81VP0 Arginase 
Q81MR1 Pyruvate dehydrogenase 
Q81TC4 NADPH-dependent 7-cyano-7-deazaguanine reductase 
Q81RP3 NH(3)-dependent NAD(+) synthetase 
Q81KU3 3-demethylubiquinone-9 3-methyltransferase 
Q81L18 DUTPase 
Q81R24 Penicillin-binding protein 
Q81RE1 Formate--tetrahydrofolate ligase 
Q81TD1 Oligoendopeptidase F 
Q81T62 Histidinol dehydrogenase 
Q81LH1 S-adenosylmethionine:tRNA ribosyltransferase-isomerase 
Q81KI3 Molybdenum cofactor biosynthesis protein B 
Q81KP8 Thiol reductase thioredoxin 
Q81MS8 GTP-binding protein TypA 
Q81T83 Thioredoxin 
Q81U22 Ferrochelatase 1 
Q81P72 Peptidoglycan-N-acetylglucosamine deacetylase 
Q81M67 Probable butyrate kinase 
Q81PY0 Uncharacterized protein 
Q81Y62 Putative S-layer protein 
Q81RT6 Nitroreductase 
Q81KX5 Metallopeptidase 
Q81Z93 Chemotaxis protein 




Q81UR3 Efflux transporter periplasmic adaptor subunit 
Q81L80 D-alanyl-D-alanine carboxypeptidase 
Q81SQ5 Xanthine phosphoribosyltransferase 
Q81TM0 Indole-3-glycerol phosphate synthase 
Q81T97 D-alanine--poly(phosphoribitol) ligase subunit 1 
Q8RPQ2 DNA protection during starvation protein 2 
Q81LF7 Transcriptional regulator 




Q81WI1 Uncharacterized protein 
Q81VV4 2-C-methyl-D-erythritol 2_4-cyclodiphosphate synthase 
Q81SF5 IMP dehydrogenase 
Q81LJ1 HTH-type transcriptional regulator CymR 
Q81XP1 HAD family hydrolase 
Q81UB2 FMN-dependent NADH-azoreductase 1 
Q81XK7 Uncharacterized protein 
Q81TC7 7-cyano-7-deazaguanine synthase 
Q81ZG9 Phosphoribosylglycinamide formyltransferase 
Q81TE0 2-aminoethylphosphonate--pyruvate transaminase 
Q81M87 DUF3932 domain-containing protein 
Q81KA6 2-dehydro-3-deoxyphosphooctonate aldolase 
Q81L14 Threonine--tRNA ligase 
Q81L31 Phenylalanine--tRNA ligase beta subunit 
Q81XS5 Probable cytosol aminopeptidase 
Q81W25 Serine--tRNA ligase 
Q81ML7 Alpha-amylase 




Q81US7 LytR family transcriptional regulator 
Q81X56 Thioredoxin reductase 
Q81L80 D-alanyl-D-alanine carboxypeptidase 
Q81VQ9 Adenylate kinase 
Q81JG0 3-oxoacyl-[acyl-carrier-protein] synthase 3 protein 1 
Q81JI7 50S ribosomal protein L9 
Q81WK8 30S ribosomal protein S2 
Q81SQ5 Xanthine phosphoribosyltransferase 
Q81LJ1 HTH-type transcriptional regulator CymR 
Q81KY8 Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta 
Q81Z66 UPF0435 protein BA_0406/GBAA_0406/BAS0392 
Q81SP8 Uncharacterized protein 
Q81W25 Serine--tRNA ligase 
Q81SB6 Uncharacterized protein 
Q81MQ2 2_3_4_5-tetrahydropyridine-2_6-dicarboxylate N-acetyltransferase 
Q81L80 D-alanyl-D-alanine carboxypeptidase 
Q81VQ9 Adenylate kinase 
Q81SQ5 Xanthine phosphoribosyltransferase 
Q81U05 Lipoate--protein ligase 
Q81KU5 NAD kinase 2 
Q81WQ6 Stage V sporulation protein S 
Q81ZG9 Phosphoribosylglycinamide formyltransferase 
Q81WI7 Acyl carrier protein 
Q81RT9 Putative lipoprotein 
Q81Y62 Putative S-layer protein 
Q81L31 Phenylalanine--tRNA ligase beta subunit 
Q81US7 LytR family transcriptional regulator 




Q81W25 Serine--tRNA ligase 
Q81L46 Iron compound ABC transporter_ iron compound-binding protein 
Q81JG0 3-oxoacyl-[acyl-carrier-protein] synthase 3 protein 1 
Q81KX5 Metallopeptidase 
Q81L80 D-alanyl-D-alanine carboxypeptidase 
Q81MQ2 2_3_4_5-tetrahydropyridine-2_6-dicarboxylate N-acetyltransferase 
Q81VQ9 Adenylate kinase 
Q81JI7 50S ribosomal protein L9 
Q81PH9 Probable manganese-dependent inorganic pyrophosphatase 
Q81KU5 NAD kinase 2 
Q81QP3 Cold-shock protein 
Q81RQ5 Petrobactin biosynthesis protein AsbE 
Q81WK8 30S ribosomal protein S2 
Q81LJ1 HTH-type transcriptional regulator CymR 
Q81W26 Pyridoxal 5'-phosphate synthase subunit PdxT 








Appendix 6 – List of Synthetic Peptides 
 
rPA peptides 
1. NTGTAPIYNVLPTTS (PA 397-411) 
2. PTTSLVLGKNQTLAT (PA 408-422) 
3. DTGSNWSEVLPQIQE (PA 501-515) 
4. QIQETTARIIFNGKD (PA 512-526) 
5. KYNDKLPLYISNPNY (PA 709-723) 
6. NPNYKVNVYAVTKEN (PA 720-734) 
7. SDNLQLPELKQKSSN (PA 177-191) 
8. KSSNSRKKRSTSAGP (PA 188-202) 
9. EKWSTASDPYSDFEK (PA 253-267) 
10. DFEKVTGRIDKNVSP (PA 264-278) 
11. NVSPEARHPLVAAYP (PA 275-289) 
12. AVGADESVVKEAHRE (PA 633-647) 
13. AHREVINSSTEGLLL (PA 644-658) 
14. GLLLNIDKDIRKILS (PA 655-669) 
 
rLF peptides 
1. QSEKEYIRIDAKVVP (LF 570-584) 
2. KVVPKSKIDTKIQEA (LF 581-595) 
3. KVTNYLVDGNGRFVF (LF 650-664) 
4. RFVFTDITLPNIAEQ (LF 661-675) 
5. IAEQYTHQDEIYEQV (LF 672-686) 
6. YEQVHSKGLYVPESR (LF 683-697) 
7. LRNDSEGFIHEFGHA (LF 710-724) 
8. FGHAVDDYAGYLLDK (LF 721-735) 
9. DALLHQSIGSTLYNK (LF 453-467) 




10. LYNKIYLYENMNINN (LF 464-478) 
11. NINNLTATLGADLVD (LF 475-489) 
12. RAGYLENGKLILQRN (LF 543-557) 
13. LQRNIGLEIKDVQII (LF 554-568)
Appendix 7 – Samples that were tested for cytokine response to rPA, rLF, IMA/PNA and 




1 2 3 4 5 6 7 8 9 10 
Blank X X X X X X X X X X 
rPA X X X X X X X X X X 
rLF X X X X X X X X X X 
IMA/PNA X X X X X X X X X X 
PA1 mix X X X X X X X X X X 
PA2 mix X X X X X X X X X X 
PA3 mix X X  X X  X X X X 
PA4 mix  X  X X  X X X X 
PA5 mix  X  X X  X X X X 
LF1 mix  X  X X  X X X  
LF2 mix  X  X X  X X X  
LF3 mix  X  X X  X X X  
LF4 mix  X   X  X X X  
  
 
 
